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Calcium-independent phospholipase A2 (iPLA2) is an 85 kDa enzyme 
that releases docosahexaenoic acid (DHA) from glycerophospholipids. 
Prefrontal cortical iPLA2 has been shown to be important in hippocampo-
prefrontal cortical LTP and for the antidepressive effect of the antidepressant, 
maprotiline. In the first part of the study, we investigated the role of prefrontal 
cortical iPLA2 in the antinociceptive effect of maprotiline and another TCA, 
amitriptyline. Antidepressant treatment reduced pain behavioral responses 
indicating antinociceptive effect of maprotiline and amitriptyline treatment in 
a model of inflammatory orofacial pain. Injection of antisense oligonucleotide 
to iPLA2 in the dorsolateral prefrontal cortex abolished the antinociceptive 
effect of maprotiline but not amitriptyline. In contrast, iPLA2 antisense 
injection in the somatosensory cortex had no effect on maprotiline-induced 
antinociception. Real-time RT-PCR and Western blot results showed 
increased iPLA2 mRNA and protein expression in the prefrontal cortex after 
maprotiline administration, thereby suggesting that prefrontal cortical iPLA2 is 
involved in the antinociceptive effect of maprotiline. Lipidomic analysis 
showed decreased PC and increased LPC species in the prefrontal cortex after 
maprotiline treatment, indicating increased iPLA2 enzymatic activity and 
endogenous release of DHA and EPA. These changes were blocked by 
intracortical iPLA2 antisense injection. Together, our results indicate an 
important role of prefrontal cortical iPLA2 in the antinociceptive effect of 
maprotiline, thereby suggesting a role of iPLA2 not only in the antidepressive, 





In the second part of the study, we elucidated the potential cellular 
mechanisms involved in iPLA2 expression induction, in particular the 
stimulation of adrenergic receptors. Treatment of SH-SY5Y neuroblastoma 
cells with maprotiline and another TCA with strong noradrenaline reuptake 
inhibition activity, nortriptyline, as well as the alpha-1 adrenergic receptor 
agonist, phenylephrine, resulted in increased iPLA2 expression. This increase 
was blocked by inhibitors to the alpha-1 adrenergic receptors, MAPK/ERK, 
and sterol regulatory element binding protein (SREBP). Maprotiline and 
phenylephrine induced binding of SREBP-2 to the SRE region on the iPLA2 
gene, as determined by electrophoretic mobility shift assay (EMSA). Our 
results indicate that stimulation of adrenergic receptors increased iPLA2 
expression via MAPK/ERK and SREBP-2 
Docosanoids such as resolvin D1 (RvD1) have been shown to be 
effective in treatment of inflammatory conditions and pain. RvD1 is 
metabolized from DHA by 15-lipoxygenase (15-LOX). In the last part of the 
study, we postulate that besides inducing iPLA2 expression, antidepressants 
with strong noradrenaline reuptake inhibition activity will similarly induce an 
increase in 15-LOX expression. Real-time RT-PCR showed a significant 
increase in 15-LOX mRNA expression after maprotiline and nortriptyline 
treatment which was blocked by prazosin. This was supported by Western blot 
analysis which showed similar results. Overall, our findings suggest that 
treatment with antidepressants, especially those with strong noradrenaline 
reuptake inhibition activity, will induce iPLA2 expression leading to increased 
DHA levels and subsequent production of resolvins via a concurrent increase 




then contribute to the antidepressant-induced antinociception by facilitating 
activity or plasticity in the dorsolateral prefrontal cortex to stimulate the PAG 
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1. Glycerophospholipids in the brain 
 Glycerophospholipids are glycerol-based phospholipids which are 
amphipathic in nature with nonpolar and polar ends (Farooqui et al., 2000a). 
They are present in relatively high levels in brain tissue and consist of up to 20 
to 25 % of the dry weight in the adult brain (Farooqui et al., 2000a). Together 
with cholesterol and glycolipids, glycerophospholipids encompass 
approximately 50 to 60 % of the whole membrane mass in the neural 
membrane (Farooqui et al., 2000a). There are four main categories of 
glycerophospholipids in the neural membrane. Three of these four categories 
contain a glycerol backbone with a normally unsaturated fatty acid at the 
carbon-2 position and a phosphobase at the carbon-3 position of the glycerol 
moiety which is made up of either ethanolamine, serine, inositol or choline 
(Farooqui et al., 2000a). They include 1-alkyl-2-acyl glycerophospholipid, 
1,2-diacyl glycerophospholipid and 1-alk-1’-enyl-2-acyl glycerophospholipid 
or plasmalogen (Farooqui et al., 2000a). The last type of glycerophospholipid 
consists of sphingomyelin which contains phosphocholine-linked ceramide at 
the primary hydroxyl group (Farooqui et al., 2000a). 
 Glycerophospholipids play an important role in neural membrane 
fluidity, stability and permeability (Farooqui et al., 2000a). They are involved 
in membrane molecular packing, charge and reactivity and are essential for 
regulation of membrane-bound ion channel and enzyme activity (Crews, 1982; 
Farooqui et al., 2000a). Besides their role in neural membranes, 
glycerophospholipids are important for membrane anchoring (Farooqui et al., 
2000a). Glycans, phosphoethanolamines and phosphatidylinositols (PIs) form 
glycosylphosphatidylinositol anchors that attach important proteins to 
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biomembranes (Low, 1989; Englund, 1993). The attached proteins include 
enzymes such as aminopeptidase P, alkaline phosphatase, acetylcholinesterase, 
5’-nucleotidase and carboxypeptidase M which are present in all brain tissue 
and are essential for numerous metabolic activities (Hooper, 1997). Proteins 
such as axonin-1, transient axonal glycoprotein-1 (TAG-1) and the neural cell 
adhesion molecule are also linked to the glycosylphosphatidylinositol anchor 
and were found to activate axonal elongation and neurite outgrowth in PC12 
rat cells (Doherty and Walsh, 1993). Endocytosis, fusion and secretory granule 
formation are examples of several membrane trafficking processes that also 
involve polyphosphoinositides (Martin, 1997).  
 In addition, glycerophospholipids are involved in regulation of 
enzymatic functions and they are needed for a number of enzymes to carry out 
their activity (Farooqui et al., 2000a). Some of these enzymes require specific 
glycerophospholipids and one such example is protein kinase C (PKC) which 
is activated in the presence of phosphatidylserine (PS) (Spector and Yorek, 
1985; Yeagle, 1989; Farooqui et al., 2000a). PKC activation involves linkage 
with neural membranes via PS in the presence of calcium ions which will 
increase neural membrane surface pressure to help insert the protein domain of 
PKC into the membrane (Orr and Newton, 1992; Farooqui et al., 2000a). Once 
inserted into the membrane, PKC will then bind to diacylglycerol (DAG) to be 
fully functional (Farooqui et al., 1988; Farooqui et al., 2000a). 
Glycerophospholipids also act as precursors for DAG and it was suggested 
that DAG changes the membrane bilayer properties linked with lipid 
hexagonal-phase propensity in the activation of PKC (Senisterra and Epand, 
1993). Moreover, DAG promotes membrane fusion which is associated with 
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the release of neurotransmitters (Nieva et al., 1989). By regulating PKC 
function, PS can likewise affect the binding activity of AMPA receptors with 
subsequent effects on synaptic plasticity (Gagne et al., 1996). PS also 
regulates the activities of acetylcholine receptor channel, Na+/ K+-ATPase, B-
Raf protein kinase, dynamin GTPase and DAG kinase, while PC is needed for 
the activity of the inner mitochondria enzyme, β-Hydroxybutyrate 
dehydrogenase (Sunshine and McNamee, 1992; Farooqui et al., 2000a). 
Specific phospholipids are also needed by enzymes such as adenylate cyclase 
(AC) and Ca2+-ATPase which are involved in sustaining regular ion 
homeostasis in glial cells and neurons (Farooqui and Horrocks, 1985; Spector 
and Yorek, 1985). Any disease-induced changes in the composition of 
glycerophospholipids can potentially affect ion permeability and fluidity of the 
membrane which will subsequently induce unregulated influx of calcium ions 
(Mecocci et al., 1996). This, in turn, will lead to oxidative stress and 
inflammatory responses in the brain (Farooqui and Horrocks, 1994). 
Glycerophospholipids also act as a reservoir for the production of a 
number of bioactive mediators and lipid second messengers (Dennis et al., 
1991; Exton, 1994; Farooqui et al., 1995; Farooqui et al., 1997b). Different 
second messengers are produced depending on the type and activity of the 
phospholipase involved (Dennis et al., 1991; Exton, 1994; Farooqui et al., 
1995; Farooqui et al., 1997b). Phospholipases are a group of enzymes that 
hydrolyze glycerophospholipids and are classified according to their site of 
action (Fig. 1.1) (Farooqui et al., 2000a). The ester bond at the sn-1 position is 
acted on by phospholipase A1 (PLA1) to form a 2-acyl lysophospholipid and 
free fatty acid while phospholipase A2 (PLA2) hydrolyzes the fatty acid ester 
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bond at the sn-2 position to produce a 1-acyl lysophospholipid and free fatty 
acid (Farooqui et al., 2000a). The 1-acyl lysophospholipid produced by PLA2 
can then undergo subsequent acylation by acyl-Coenzyme A (acyl-CoA) in the 
presence of acyltransferase or it can be hydrolyzed by lysophospholipase to 
form a phosphobase and fatty acid (Farooqui et al., 2000a). The 
phosphodiester bond sn-3 position is cleaved by phospholipase C (PLC) to 
produce a phosphobase and DAG while phospholipase D (PLD) hydrolyzes 
glycerophospholipids to form a free base and phosphatidic acid (Farooqui et 
al., 2000a). The free fatty acids produced by phospholipase are active 
signaling molecules and their signaling actions are stopped by their conversion 
to fatty acyl-CoA (Horrobin, 2001). Acyl-CoA:lysophospholipid 
acyltransferase can then reacylate fatty acyl-CoA together with 
lysoglycerophospholipids to form glycerophospholipids (Lands, 1958). All 
four groups of phospholipases have several isoforms which are present in the 
brain and they have been purified and characterized from brain tissue 
(Hirashima et al., 1992; Rhee and Choi, 1992; Pete et al., 1994; Ross et al., 
1995; Negre-Aminou et al., 1996; Exton, 1997, 1999; Farooqui et al., 2000a). 
Phospholipase activity on glycerophospholipids to produce lipid 
second messengers are part of a signal transduction system which can 
potentially contribute to cross-talk between effector systems that are regulated 
by receptors and are important for regular glial cell and neuronal growth 
maintenance (Farooqui et al., 1992; Farooqui et al., 2000a). A common 
agonist was found to activate all four groups of phospholipases and the 
products of individual phospholipases were shown to stimulate other 
phospholipases, supporting the presence of a cross-talk between these 
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enzymes (Clark et al., 1995; Farooqui et al., 2000a). PLC activation produces 
DAG which translocates and stimulates PKC to activate both PLD and PLA2 
(Farooqui et al., 2000a). Besides producing DAG, PLC activity on PI 4,5-
bisphosphate also results in the production of inositol 1,4,5-trisphosphate (IP3) 
which is involved in intracellular calcium release and subsequent calcium 
signaling processes (Farooqui and Horrocks, 2007). PLC has been implicated 
in the maintenance of cell proliferation, secretion, contraction and 
phototransduction (Rhee and Choi, 1992). 
PLD-generated second messengers include phosphatidic acid and 
choline which are hydrolyzed from PC in response to a number of 
extracellular stimuli (Klein et al., 1995; Exton, 1997, 1999). Phosphatidic acid 
acts as a precursor for lysophosphatidic acid which has autocrine or paracrine 
signaling effects and can activate the G protein-coupled receptor mechanism 
to trigger tyrosine kinase activation and subsequent Ras-Raf-MAPK 
stimulation (Moolenaar, 1995). Lysophosphatidic acid is present in high levels 
in the brain and the highest level of lysophosphatidic acid binding proteins and 
receptors are found in brain tissue (Das and Hajra, 1989). Lysophosphatidic 
acid causes retraction of neurites and rounding of neuronal cells in 
neuroblastoma cells and reduced uptake of glucose and glutamate in astrocytes 
(Tokumura, 1995; Keller et al., 1996). AC activity is also inhibited by 
phosphatidic acid and lysophosphatidic acid via a pertussis-toxin sensitive 
procedure which, in turn, causes a decrease in cAMP levels (Farooqui et al., 
2000a). Besides acting as a precursor for lysophosphatidic acid, phosphatidic 
acid is involved in the activation of enzymes such as PLC, PKC, 
monoacylglycerol acyltransferase and PI 4-kinase (Farooqui et al., 2000a). 
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Moreover, phosphatidic acid was found to increase the GTP-bound form of 
Ras (Farooqui et al., 2000a). PLD also has a role in inflammation, cell 
proliferation, diabetes oncogenesis, secretion, mitogenesis and membrane 
trafficking (Exton, 1994; Liscovitch, 1996; Jones et al., 1999).  
PLA2 activity produces arachidonic acid (AA) which can be further 
metabolized into eicosanoids such as leukotrienes, prostaglandins and 
thromboxanes (Wolfe and Horrocks, 1994). AA is involved in pathological as 
well as physiological activities and it was shown to control ion channels and 
regulate DAG kinase, protein kinase A (PKA), PKC, Na+/ K+-ATPase and 
NADPH oxidase enzymatic activity (Dennis et al., 1991; Farooqui et al., 
1997a; Farooqui et al., 2000a). AA was also shown to affect excitatory amino 
acid transporter-mediated glutamate uptake (Volterra et al., 1994). 
Additionally, AA and eicosanoids are known to be involved in the activation 
of PLD (Klein et al., 1995). Eicosanoids also act as intracellular second 
messengers which are essential for oxidative stress, inflammation and cell 
proliferation regulation (Farooqui, 2009a). In addition, they are involved in 
blood flow regulation, behavioral control and regulation of immune and neural 
activities (Chiu and Richardson, 1985; Wolfe and Horrocks, 1994; Katsuki 
and Okuda, 1995). Furthermore, PLA2 is involved in the production of 
lysophospholipids which play important roles in membrane-membrane and 
membrane protein interactions (Fuller and Rand, 2001). Lysophospholipids 
also act as precursors for platelet activating factor (PAF) (Farooqui et al., 
2000a; Fuller and Rand, 2001). One of the lysophospholipids, 
lysophosphatidylcholine (LPC), was found to activate alkaline phosphatase, 
PKC, phenylalanine hydroxylase, glycosyltransferase, sialyltransferase and 
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3,5-nucleotide phosphodiesterase while inhibiting lysophospholipase, AC, 
acyl-CoA:lysophosphatidylcholine acyltransferase and guanylate cyclase 
(Weltzien, 1979). PLA2 is also involved in regeneration, apoptosis, 
neurodegeneration and neuritogenesis (Farooqui et al., 1997b). 
 
 
Fig. 1.1 Phospholipase enzymes and their site of action. Adapted from 
(Farooqui et al., 2000a) 
 
1.1. Phospholipase A2 
 Phospholipase A2 (PLA2, EC 3.1.1.4), as mentioned previously, 
comprises a group of enzymes that hydrolyze the acyl ester bond at the sn-2 
position to produce a 1-acyl lysophospholipid and free fatty acid such as AA 
from glycerophospholipids (Dennis, 1994; Farooqui et al., 2000a). They are 
commonly found in mammalian tissue and can be further divided into several 
groups depending on their enzymatic reaction, structure, cellular location and 
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function (Farooqui et al., 1997b). PLA2 enzymes include secretory 
phospholipase A2, cytosolic phospholipase A2, plasmalogen-selective 
phospholipase A2 and calcium-independent phospholipase A2 (Dennis, 1994; 
Farooqui et al., 1997b). There are different isozymes for each type of PLA2 
(Dennis, 1994; Farooqui et al., 1997b) 
 
1.1.1. Secretory phospholipase A2 
 Secretory phospholipase A2 (sPLA2) is produced intracellularly and is 
secreted to act on glycerophospholipids extracellularly (Farooqui and 
Horrocks, 2007). The sPLA2 enzyme family consist of eleven isozymes which 
can be found in mammalian tissues and they are named in the order of their 
discovery: sPLA2-IB, -IIA, -IIC, -IID, -IIE, -IIF, -III, -V, -X, -XIIA and -XIIB 
(Kudo and Murakami, 2002). It was suggested that each sPLA2 isozyme 
hydrolyzes specific phospholipid membrane moieties due to their distinct 
tissue expression patterns and diverse enzymatic activity (Murakami and 
Kudo, 2004).  
sPLA2 enzymes have low molecular mass (14-19 kDa), high content of 
disulfide bonds and are structurally related due to a common His-Asp catalytic 
dyad (Murakami and Kudo, 2004; Yang et al., 2009). Activation of sPLA2 
enzymatic activity requires Ca2+ in the millimolar range before they can act on 
the sn-2 ester bond without strict preference for any particular fatty acid side 
chain of the glycerophospholipids (Murakami and Kudo, 2002; Schaloske and 
Dennis, 2006; Farooqui and Horrocks, 2007; Burke and Dennis, 2009). sPLA2 
has low activity in the olfactory bulb and cerebellum, moderate activity in the 
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thalamus, hypothalamus and cerebral cortex, and has the highest levels of 
activity in the pons, hippocampus and medulla oblongata (Thwin et al., 2003).  
Certain sPLA2 isozymes, especially sPLA2-IIA, have been suggested to 
be involved in inflammation, given that sPLA2-IIA and sPLA2-V were found 
to be highly expressed during inflammation resolution (Gilroy et al., 2004). In 
addition to acting on glycerophospholipids such as phosphatidylglycerol, 
sPLA2-IIA is involved in the production of AA from cellular membranes, 
consequently enhancing the effects of AA on the inflammatory pathway 
(Hanasaki et al., 1999). sPLA2-IIA sera concentrations are linked with the 
seriousness of inflammatory disorders, which is exemplified by the high 
catalytic sPLA2-IIA level in the synovial fluids of rheumatoid arthritis and 
osteoarthritis patients (Nakano et al., 1990; Crowl et al., 1991; Oka and Arita, 
1991; Pruzanski et al., 1991; Pruzanski et al., 1995). Inflammatory responses 
were also increased after sPLA2-IIA injection into the hind paw of rats with 
adjuvant arthritis, further supporting the involvement of sPLA2-IIA in 
inflammatory pain (Murakami et al., 1990; Koike et al., 1997).  
 
1.1.2. Cytosolic phospholipase A2 
The enzymes in the cytosolic phospholipase A2 (cPLA2) family have 
high molecular weights (85-110 kDa) and consist of cPLA2α, cPLA2β, cPLA2γ, 
cPLA2δ, cPLA2ε and cPLA2ζ, where cPLA2α, cPLA2β and cPLA2γ are localized 
in brain tissue (Molloy et al., 1998; Pickard et al., 1999; Balboa et al., 2002). 
cPLA2α is primarily expressed in gray matter astrocytes while maintaining 
very low levels in glial and neuronal cells (Owada et al., 1994; Farooqui et al., 
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2000b; Ong et al., 2010). cPLA2β is predominantly present in the cerebellum 
while cPLA2γ is mainly found in the heart, skeletal muscle and brain (Pickard 
et al., 1999; Ong et al., 2010). All three isoforms were shown to be expressed 
in the amygdala, thalamus, corpus callosum, hippocampus, subthalamic 
nucleus and substantia nigra (Schaeffer et al., 2010). Although there are very 
low levels of cPLA2 present in the liver, kidney, pancreas and heart, cPLA2 is 
still found in most peripheral tissues (Molloy et al., 1998). cPLA2 expression 
was also shown to be localized in dendritic spines or dendrites in the spinal 
cord ventral and dorsal horn (Sandhya et al., 1998; Ong et al., 1999a).  
cPLA2 catalytic activity does require need Ca
2+ but submicromolar 
concentrations of Ca2+ are necessary for its translocation to internal 
membranes from the cytosol so that it can undergo phosphorylation for its 
enzymatic activity (Farooqui et al., 2000b; Murakami and Kudo, 2002). cPLA2 
preferentially acts on AA at the sn-2 position as compared to other unsaturated 
fatty acids in phospholipid substrates to produce lysophospholipids and AA 
(Diez et al., 1992; Clark et al., 1995; Balsinde et al., 2006). As previously 
mentioned, lysophospholipids, AA and its metabolite eicosanoids, are highly 
involved in physiological and pathological processes. Hence, regulation of 
cPLA2 activity is necessary to maintain concentrations of lysophospholipids 
and AA for cellular homeostasis (Tanaka et al., 2012).  
Due to their role in producing AA, cPLA2 has been implicated in 
inflammatory processes (Leslie, 1997; Tanaka et al., 2012). Activation of 
cPLA2 by proinflammatory factors will lead to increased cPLA2 activity and 
higher levels of AA which can be further metabolized into eicosanoids that are 
involved in stimulation and maintenance of inflammatory responses (Farooqui 
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and Horrocks, 2007). Long term potentiation (LTP) induction in the dentate 
gyrus also leads to cPLA2 activation and AA generation from 
glycerophospholipids, in particular PCs (Clements et al., 1991). Depending on 
the type of cell or tissue, cPLA2 is involved in numerous other cellular 
processes such as mitogenesis, differentiation and cytotoxicity (Leslie, 1997). 
In addition, cPLA2 was suggested to have an important role in the pain 
pathway due to its localization in the brainstem’s facial motor nucleus and part 
of the ascending auditory pathway which includes the cochlear nuclei 
(Sandhya et al., 1998; Kishimoto et al., 1999; Ong et al., 1999b; Shirai and Ito, 
2004). Intrathecal administration of cPLA2 inhibitors significantly reduced 
cPLA2 activity in spinal homogenates, which suggest the involvement of 
cPLA2 in spinal processing of nociceptive inputs (Lucas et al., 2005). PLA2 
inhibitors similarly lessen the production of excitatory amino acids from the 
cortex after ischemia (Phillis and O'Regan, 1996). cPLA2 activity was also 
found to be elevated in the dentate granule gyrus after brain ischemia which 
could induce higher neural membrane phospholipid metabolism and 
subsequent production of AA-derived lipid metabolites leading to oxidative 
stress, neurodegeneration, nociception and neuroinflammation (Koike et al., 
1997; Ong et al., 2010). An increase in expression of both cPLA2 mRNA and 
protein was demonstrated after transient forebrain ischemia or excitotoxicity 
injury followed by increased concentration of a toxic lipid peroxidation 
product, 4-hydroxynonenal (Owada et al., 1994; Clemens et al., 1996; 
Sandhya et al., 1998; Ong et al., 2003). 4-hydroxynonenal level was reduced 
after cPLA2 inhibitor treatment which induced a neuroprotective influence on 
hippocampal neurons after excitotoxicity damage (Lu et al., 2001). cPLA2 
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inhibitor treatment also increased functional recovery in spinal cord damage 
and protected hippocampal neurons against oxygen-glucose deficit (Arai et al., 
2001; Huang et al., 2009). 
 
1.1.3. Plasmalogen-selective phospholipase A2 
Plasmalogen-selective phospholipase A2 (PlsEtn-selective PLA2) has a 
molecular weight of 39 kDa and is found in the cytosol (Yang et al., 1996). 
PlsEtn-selective PLA2 is involved in a receptor-mediated metabolism of 
plasmalogens in neural membranes and does not require Ca2+ for its enzymatic 
activity (Yang et al., 1996). PlsEtn-selective PLA2 preferentially acts on AA 
and docosahexaenoic acid (DHA) at the sn-2 position of plasmalogens to 
generate free fatty acids and lysoplasmalogens (Farooqui and Horrocks, 
2001a). The rate of release of DHA was found to be three to five times faster 
compared to AA (Ong et al., 2010). Plasmalogens contain a particularly high 
DHA content, where close to 70 % of plasmalogens in neuronal membranes 
possess DHA at the sn-2 position (Farooqui and Horrocks, 2001b). PlsEtn-
selective PLA2 is mainly linked with astrocytes due to its co-localization with 
glial fibrillary acidic protein (Farooqui and Horrocks, 2001a). Gangliosides, 
glycosaminoglycans and sialoglycoproteins were found to strongly inhibit 
PlsEtn-selective PLA2 and the interaction between glycoconjugates and 
PlsEtn-selective PLA2 is involved in the regulation of its enzymatic activity 
(Yang et al., 1996). PlsEtn-selective PLA2 hydrolyzes plasmalogen to generate 
second messengers such as eicosanoids under physiological conditions. 
However, PlsEtn-selective PLA2 was implicated to substantially release free 
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fatty acid under pathological settings which may lead to significant cellular 
and tissue injury (Yang et al., 1996).  
PlsEtn-selective PLA2 activity was also suggested to have a role in 
Alzheimer’s disease, exemplified by the increased activity in the nucleus 
basalis and hippocampal areas in the brain of Alzheimer’s disease patients 
(Farooqui, 2010). PlsEtn-selective PLA2 was found to be activated by a 
sphingolipid metabolism lipid mediator, ceramide, in a dose-dependent 
manner (Latorre et al., 2003). It was then suggested that increased PlsEtn-
selective PLA2 activity in Alzheimer’s disease patients may be attributed to 
ceramide build-up in the brain (Han et al., 2002; Han, 2005; Farooqui, 2010). 
Increased PlsEtn-selective PLA2 activity may also lead to plasmalogen deficit 
and synapse loss in the brain of Alzheimer’s disease patients (Wells et al., 
1995; Ginsberg et al., 1998; Guan et al., 1999; Han et al., 2001; Pettegrew et 
al., 2001). Deficits in ethanolamine plasmalogen may induce destabilization of 
the neural membrane by affecting the core temperature needed for membrane 
lipid bilayer stability (Ginsberg et al., 1998; Farooqui, 2009b). Excessive 
PlsEtn-selective PLA2 activity may similarly cause an increase in 
lysoplasmalogen production which may affect membrane permeability and 
fluidity as well as permit calcium influx, leading to neural membrane 
destabilization (Farooqui et al., 2008). Serum plasmalogen concentrations are 
also associated with severity of dementia and Alzheimer’s disease 
neuropathology (Goodenowe et al., 2007). In addition to being associated with 
Alzheimer’s disease, PlsEtn-selective PLA2 activity was also found to be up-
regulated in neuronal cell cultures undergoing kainate-induced toxicity and 
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ischemic damage in heart disease (Farooqui et al., 2001; Farooqui et al., 
2008). 
 
1.1.4. Calcium-independent phospholipase A2 
 Calcium-independent phospholipase A2 (iPLA2) was originally 
purified and characterized from the murine P388D1 macrophage-like cell line 
and has a molecular weight of 80-88 kDa (Ackermann et al., 1994; Murakami 
and Kudo, 2002; Farooqui and Horrocks, 2007). Besides its phospholipase A2 
activity, iPLA2 has additional lysophospholipase activity and was 
demonstrated to have intricate interactions with interfaces (Lio and Dennis, 
1998). iPLA2 activity does not require Ca
2+ but it utilizes a catalytic serine and 
can be affected by lipid coupled serine-reactive-type blockers (Ackermann et 
al., 1995; CondeFrieboes et al., 1996; Lio et al., 1996; Murakami and Kudo, 
2002; Farooqui and Horrocks, 2007). Although iPLA2 was suggested to not 
have a significant fatty acid selectivity, it has been shown to preferentially act 
on linoleic acid and DHA at the sn-2 position (Murakami and Kudo, 2002; 
Farooqui et al., 2006; Rapoport, 2013). iPLA2 is strongly inhibited by the 
blocker, bromoenol lactone, while its activity is enhanced by ATP (Farooqui 
and Horrocks, 2007). iPLA2 mRNA can be found in all tissues, with a higher 
expression in the central nervous system (CNS) and lower levels in the testes, 
pancreas and spleen at the periphery (Molloy et al., 1998; Lucas et al., 2005). 
Three iPLA2 isoforms have been found in brain tissues and they include 
iPLA2α, iPLA2β and iPLA2γ (Molloy et al., 1998; Zanassi et al., 1998; Balboa 
et al., 2002). There is a significantly higher expression of iPLA2 in the brain 
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compared to cPLA2, evidenced by iPLA2 immunohistochemical studies where 
dense staining of iPLA2 was observed in the striatum, cortex and hippocampus 
(Farooqui et al., 1999; Ong et al., 2005; Ong et al., 2010). Neurons and 
astrocytes have been shown to express iPLA2 in the brain (Ong et al., 2005; 
Sun et al., 2005) 
 iPLA2 is an important “housekeeping” enzyme. Studies showed that 
knockdown of the iPLA2 gene affected the incorporation of AA in 
phospholipids of the murine P388D1 macrophage cells, implicating its role in 
the maintenance and remodeling of phospholipids via constitutive deacylation 
of phospholipids (Balsinde et al., 1995; Balsinde et al., 1997). Besides its role 
in phospholipid remodeling, iPLA2 is also involved in the release of 
neurotransmitters, LTP, signal transduction, learning and memory (Winstead 
et al., 2000; Farooqui and Horrocks, 2007; Shalini et al., 2014). Bromoenol 
lactone treatment inhibited LTP induction in hippocampal slices and induced 
nuclear deterioration and neurite loss in cortical neurons (Wolf et al., 1995; 
Kurusu et al., 2008). Administration of bromoenol lactone at the hippocampus 
also affected short-term and long-term memory acquisition in inhibitory 
avoidance learning (Schaeffer and Gattaz, 2005). Similarly, iPLA2 knockdown 
in the prefrontal cortex abolished hippocampo-prefrontal cortex LTP induction 
and inhibited spatial working memory (Shalini et al., 2014). iPLA2 also has a 
possible role in the cortex-striatum-thalamus-cortex circuitry where inhibition 
of iPLA2 induced vacuous chewing movements in a rat model for tardive 
dyskinesia (Lee et al., 2007). Moreover, intrastriatal knockdown of iPLA2 
induced deficits in prepulse inhibition of the auditory startle reflex in rats, 
similar to the prepulse inhibition deficits observed in schizophrenic patients 
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(Braff et al., 1978; Braff et al., 2001; Lee et al., 2009). iPLA2 is also involved 
in the protection of mitochondrial processes from oxidative injury and in 
maintaining the structure of a mitochondrial membrane lipid component, 
cardiolipin, for the electron transport chain mechanism (Seleznev et al., 2006; 
Kinsey et al., 2008). In addition, prefrontal cortical iPLA2 activity was 
decreased in a frontal variant of Alzheimer’s disease (Talbot et al., 2000). 
 iPLA2 has another significant role in its capacity to generate DHA 
from brain glycerophospholipids where iPLA2 deficiency caused a decrease in 
brain DHA signaling and metabolism (Strokin et al., 2003, 2007; Green et al., 
2008; Basselin et al., 2010). Inhibition of iPLA2 using bromoenol lactone or 
small interfering RNA suppressed the release of DHA without affecting AA 
production in astrocytes after ATP stimulation (Strokin et al., 2003, 2007). 
DHA is metabolized into docosanoids such as resolvins and neuroprotectins 
which have anti-inflammatory actions and are involved in synaptic plasticity 
and cell survival signaling (Tassoni et al., 2008; Bazan, 2009; Xu et al., 2010; 
Park et al., 2011; Serhan and Petasis, 2011). They are also potentially involved 
in neuroprotective actions against ischemia-reperfusion injury (Marcheselli et 
al., 2003).  
 
1.2. Polyunsaturated fatty acids 
 Polyunsaturated fatty acids (PUFAs) are long-chain fatty acids that 
include omega-6 fatty acids and omega-3 fatty acids such as DHA (Fig. 1.2) 
(Farooqui, 2009b). They have more than one double bond in their backbone 
and are derived from the essential fatty acids, omega-3 α-linolenic acid (ALA; 
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18:3) and omega-6 linoleic acid (LA; 18:2) (Logan, 2003; Scorletti and Byrne, 
2013). Plants are able to synthesize ALA via the Δ-15 desaturase enzyme 
which is absent in mammals (Scorletti and Byrne, 2013). Thus, the 
aforementioned essential fatty acids must be obtained from dietary sources 
such as walnuts and fish as these fatty acids cannot be produced by the human 
body (Logan, 2003; Scorletti and Byrne, 2013). Elongase and desaturase 
enzymes are involved in the conversion of ALA and LA to PUFAs (Fig. 1.3) 
(Hulbert et al., 2005). ALA is first converted to eicosapentaenoic acid (EPA; 
20:5) which is subsequently converted to DHA (22:6) while LA is converted 
to AA (20:4), the primary omega-6 fatty acid which acts as a precursor for the 
proinflammatory series of eicosanoids (Kim, 2007; Farooqui, 2009b; Scorletti 
and Byrne, 2013).  
 
 
Fig. 1.2 Structure of several PUFAs. Adapted from (Farooqui, 2009b). 





Fig. 1.3 Synthesis and metabolites of omega-3 and omega-6 fatty acids as well 
as the enzymes involved. Adapted from (Scorletti and Byrne, 2013).  
 
1.2.1. DHA in the brain 
 Although there is a high level of DHA in the brain which is 
accumulated in neuronal membranes, DHA cannot be produced de novo in the 
brain as the neurons lack the necessary desaturase enzymes (Glomset, 2006; 
Kim, 2007; Nguyen et al., 2014). DHA in the body is transported by liver-
formed plasma lipoproteins through the bloodstream, whereby some of the 
DHA is imported across the blood-brain barrier and esterified to the sn-2 
position of the glycerol backbone of membrane glycerophospholipids 
(Glomset, 2006). A recent study found that the major transporter involved in 
the uptake of DHA into the brain is Mfsd2a which is a member of the major 
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facilitator superfamily and was previously an orphan transporter (Nguyen et 
al., 2014). DHA is found to be especially enriched in glycerophospholipids 
such as PCs, PSs, phosphatidylethanolamines (PEs) and ethanolamine 
plasmalogens, and comprises up to 50 % of the total quantity of PUFAs 
esterified at the sn-2 position of brain glycerophospholipids (Garcia et al., 
1998; Kim, 2007; Farooqui, 2009b). DHA is produced from ethanolamine 
plasmalogens via the activity of PlsEtn-selective PLA2 and can also be 
generated from glycerophospholipids via iPLA2 activity as shown in several in 
vitro studies (Strokin et al., 2003, 2007; Farooqui, 2009b). As stated 
previously, brain imaging of iPLA2-deficient mice also revealed reduced DHA 
signaling and metabolism, supporting the role of iPLA2 in generating DHA in 
the brain (Basselin et al., 2010). 
 Both DHA and EPA have highly fluidizing characteristics and the 
presence of DHA at the sn-2 position of glycerophospholipids aids in the 
maintenance of membrane properties such as regulation of membrane fluidity 
(Salem et al., 1986). Administration of DHA/EPA increased brain 
phosphatides and synaptic protein concentrations while AA treatment did not 
induce any effects (Cansev and Wurtman, 2007). DHA was also shown to be 
important for initiation of LTP. Administration of DHA attenuated the 
inhibitory effects of iPLA2 inhibitors on LTP induction in rat hippocampal 
slices, demonstrating the importance of DHA for LTP initiation (Fujita et al., 
2001). In addition, as stated previously, our recent study showed that 
knockdown of iPLA2 in the prefrontal cortex abolished hippocampo-prefrontal 
cortical LTP induction and inhibited spatial working memory (Shalini et al., 
2014). Taken together, results from these studies suggest that iPLA2 activation 
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and subsequent production of DHA are highly involved in synaptic plasticity, 
learning and memory. In a 2006 Framingham Heart Study, higher plasma PC 
DHA level was found to be significantly linked with a decreased risk of 
dementia development in the study subjects (Schaefer et al., 2006). Moreover, 
dietary intake of fatty fish and marine omega-3 fatty acids in middle-age 
subjects was associated with a decreased risk of impaired cognitive function in 
a cross-sectional population-based study, indicating an important role of DHA 
in learning and memory (Kalmijn et al., 2004).  
Studies have also showed a possible role of PUFAs and DHA in pain. 
Patients with chronic pain were found to possess high levels of omega-6 fatty 
acids (Tokuyama and Nakamoto, 2011). Furthermore, patients with 
rheumatoid arthritis or joint pain caused by dysmenorrhea or inflammatory 
bowel disease reported reduced pain intensity after supplementation with 
omega-3 fatty acid such as DHA (Goldberg and Katz, 2007). Additionally, 
dose-dependent administration of DHA was shown to exert antinociceptive 
effects in animal pain models (Nakamoto et al., 2010). DHA, in turn, can be 
metabolized by the 15-lipoxygenase (15-LOX) enzyme to form docosanoids 
which comprise resolvins and neuroprotectins (Farooqui, 2011). 15-LOX is 
part of the LOX family of enzymes that is non-heme, contains iron, and has a 
molecular mass of approximately 75-78 kDa (Brash, 2001; Radmark and 
Samuelsson, 2009). Resolvins and neuroprotectins have anti-inflammatory as 
well as neuroprotective properties and are able to modulate the effects of AA-
derived proinflammatory eicosanoids (Hong et al., 2003; Bazan, 2009). One of 
the neuroprotectins, neuroprotectin D1 (NPD1), has been shown to stimulate 
anti-apoptotic gene and protein expression coupled with a decrease in pro-
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apoptotic proteins which may lead to suppression of amyloid-beta 
neurotoxicity in Alzheimer’s disease (Mukherjee et al., 2004; Lukiw et al., 
2005). Resolvins, including resolvin D1 (RvD1) and resolvin E1 (RvE1), were 
also reported to significantly reduce mice inflammatory pain behavior, 
whereas NPD1 was shown to effectively reduce neuropathic pain in mice, 
further highlighting the involvement of DHA and its metabolites in mediating 
neuroinflammation and pain (Yacoubian and Serhan, 2007; Nakamoto et al., 
2010; Xu et al., 2013).  
 
2. Pain 
According to the International Association for the Study of Pain 
(IASP), pain is defined as “an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or described in terms of such 
damage” (Bonica, 1979; IASP, 1979; Merskey et al., 1994). Pain is very 
complex as well as subjective and each individual acquires the knowledge or 
application of the word through personal experiences related to damage or 
injury in early life (IASP, 1979). Pain also has a robust motivational aspect 
which could encourage withdrawal reflexes in addition to highly ordered 
avoidance and escape actions (McNeill and Dubner, 2001). This motivational 
component is essential for organisms to survive (McNeill and Dubner, 2001). 
Pain can be categorized as acute pain or chronic pain. Acute pain lasts a short 
time and resolves quickly, whereas chronic pain lasts longer and can also be 
defined as “pain that extends beyond the expected period of healing” (Turk 
and Okifuji, 2001). Chronic pain may also last for a period of several months 
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or longer, or occurs frequently for at least several months. Epidemiologic 
studies revealed that pain is one of the main reasons that patients look for 
medical attention and that the lifetime prevalence of pain indications such as 
back pain, chest pain, headache and joint pain is around 24 to 37 % (Regier et 
al., 1984; Komaroff, 1990; Kroenke, 2001; Bair et al., 2003). In Singapore, a 
large epidemiological survey on the prevalence and impact of pain revealed 
that 8.7 % of the population, which translates to more than 300000 adults, 
suffer from chronic pain (Yeo and Tay, 2009). 
There are four components of the clinical occurrence of pain, namely 
nociception, pain, suffering and pain behavior (Loeser, 2006). Nociception is 
defined as the neural system of processing and encoding noxious or harmful 
stimuli (Merskey et al., 1994). Nociception does not equate pain as each can 
occur in the absence of the other (Loeser and Treede, 2008). Nociceptors are 
involved in nociception and they are sensory receptors which are particularly 
sensitive to noxious or harmful stimuli (Merskey et al., 1994). There are two 
main categories of nociceptors: A-delta fibers and C fibers. A-delta fibers are 
lightly myelinated and are involved in mediating fast, acute and sharp pain, 
whereas the unmyelinated C fibers facilitate slower, delayed, dull and more 
diffused pain (Julius and Basbaum, 2001). Threatened or actual injury to non-
neural tissue will lead to nociceptor stimulation and subsequent nociceptive 
pain which can be either somatic or visceral (Table 1.1) (Merskey et al., 1994; 
Jann and Slade, 2007). Suffering is a negative affective reaction in the brain to 
pain or other affective conditions such as depression (Loeser, 2006). Pain 
behaviors are closely associated with suffering and include things a person 
says, does or does not do that are attributed to injury or tissue damage (Loeser, 
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2006). All pain behaviors are genuine and can be measured in a clinical 
situation (Loeser, 2006). Examples of pain behaviors include moaning, 
grimacing, and limping (Loeser, 2006). 
 
Table 1.1 Differences between somatic and visceral pain. Adapted from (Bond 
and Simpson, 2006). 
Somatic Visceral 
Well localized at site of pain Poorly localized at site of pain 
May follow somatic nerve 
distribution 
Diffused radiation 
Definite and sharp pain Ambiguous and dull 
Linked with external causes Linked with internal causes 
Pain is often constant though may be 
periodic sometimes 
Pain is often periodic and leads to 
peaks though may be constant 
sometimes 
 
2.1. Orofacial pain 
Orofacial pain is defined as “pain within the structures of the oral 
cavity and face, usually of a diffuse pattern” (Zwemer, 1998). Orofacial pain 
includes pain disorders that are linked with the hard and soft tissues of the 
neck, head, face and all of the intraoral structures (American Academy of 
Orofacial Pain and Okeson, 1996). The trigeminal nerve forms the primary 
sensory supply to the orofacial area and has a big representation in the sensory 
cortex (Renton et al., 2012). Thus, any pain in the orofacial area can actually 
lead to substantial social and functional effects, where daily social activities 
such as eating, drinking or sleeping may be affected (Renton and Yilmaz, 
2011; Renton et al., 2012). Besides common conditions such as headaches, 
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toothaches and temporomandibular disorders (TMD), orofacial pain also 
includes other rare orofacial pain disorders (Shephard et al., 2014). TMD is 
one of the most common orofacial pain disorder and has similar intensity, 
persistence and psychological impact to that of back pain (Von Korff et al., 
1988; Manfredini et al., 2011). 
 
2.2. Pain pathway 
Pain pathways involve first-order, second-order and third-order 
neurons which convey nociceptive signals from the periphery to the brain (de 
Leeuw et al., 2005). Nociceptive input is transmitted to the spinal cord or 
brainstem via the spinal or trigeminal nerve and relay in the dorsal horn or 
spinal trigeminal nucleus, before onward transmission to the thalamus (Fig. 
1.4). The ascending pain pathway involves two main systems, namely the 
lateral and medial pain system (Brooks and Tracey, 2005; de Leeuw et al., 
2005). The lateral pain system transmits information to the ventral posterior 
lateral nucleus, ventral posterior medial nucleus, and ventral posterior inferior 
nucleus of the thalamus to the somatosensory cortex (de Leeuw et al., 2005). 
When stimuli travel through this lateral pain system, contralateral brain 
activation was observed (Treede et al., 1999; Rome and Rome, 2000). The 
medial pain system primarily involves medial thalamic structures which 
include the ventral part of the ventral medial nucleus, the ventrocaudal part of 
the medial dorsal nucleus, the intralaminar nucleus and the contralateral 
nucleus which eventually relays to the cingulate cortex (de Leeuw et al., 
2005). A descending pain inhibitory pathway originating from the brainstem 
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also exists, which involves relays in the brainstem nuclei and affect all sensory 
feedbacks going up into the brainstem (Basbaum and Fields, 1984; Pertovaara 
and Almeida, 2006). The periaqueductal gray (PAG) and the nucleus raphe 
magnus (NRM) are two important components of the descending pain 
inhibitory pathway where the PAG projects to the raphe nuclei in the 
brainstem (Okeson, 2005).  Serotoninergic neurons from the raphe nuclei 
project to the dorsal horn neurons in the spinal cord or the spinal trigeminal 
nucleus and act on opioid containing neurons to cause modulation of synaptic 
transmission between the first and second order sensory neurons in the pain 
pathway to modulate nociception (Pertovaara and Almeida, 2006). Besides 
these raphe neurons, noradrenergic neurons from the locus coeruleus also form 
a descending projection that inhibits pain transmission (Martin, 2003).  
 




Fig. 1.4 Transmission of sensory inputs to the brain. Adapted from (Okeson, 
2005). 
 
2.3. Animal pain models 
 Scales and questionnaires in self-ratings of pain have been shown to be 
precise, dependable and versatile for both clinical and experimental pain 
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measurement in humans (Price et al., 1983; Mogil, 2009). However, unlike 
humans, animals cannot self-report and self-rate (Mogil, 2009). Nonetheless, 
their behavioral responses to noxious stimuli can be accurately and 
consistently scored although some behaviors such as licking an inflamed paw 
may appear to lack clinical face validity (Mogil, 2009). Some of the 
commonly used animal pain models include formalin, chronic constriction 
injury, carrageenan, spinal nerve ligation and complete Freund’s adjuvant 
(CFA) (Mogil, 2009; Hsieh et al., 2010; Jaggi et al., 2011). Formalin, CFA 
and carrageenan (Fig. 1.5) are used in inflammatory pain models where they 
are injected subcutaneously into rodents to induce orofacial pain or hind paw 
edema (Poh et al., 2009; Hsieh et al., 2010). Studies have utilized these animal 
pain models to investigate nociceptive functions of molecules or potential 
antinociceptive and anti-inflammatory effects of drug treatment which could 
shed light on the mechanisms and pathways involved (Honore et al., 2002; 
Lucas et al., 2005; Oliveira et al., 2007; Poh et al., 2012). 
 
 
Fig. 1.5 Basic structure of carrageenan. Adapted from (O'Sullivan et al., 
2010). 
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2.4. Prefrontal cortex in pain 
The prefrontal cortex is the anterior portion of the frontal lobe and 
includes Brodmann areas 9, 10, 11, 12, 46 and 47 (Fuster, 2008). The main 
role of the prefrontal cortex involves executive functions such as working 
memory, planning and decision-making (Fuster, 2008). The prefrontal cortex 
receives information from different parts of the brain such as the 
hypothalamus, the midbrain and the limbic cortex (Fuster, 2008). In turn, the 
prefrontal cortex sends fibers back to these structures with the exception of the 
basal ganglia and pontine nuclei (Fuster, 2008). For these two structures, the 
prefrontal cortex sends projections to them without receiving any in return 
(Fuster, 2008). Like the brainstem and spinal cord, the prefrontal cortex is also 
richly innervated with aminergic fibers (Jordan et al., 1994; Carvalho et al., 
2005). 
Besides being involved in executive functions, there is also evidence 
suggesting a potential role of the prefrontal cortex in pain and antinociception. 
The Brodmann areas 9 and 46 make up the dorsolateral prefrontal cortex 
which is vital for conservation of information in short-term memory, 
maintaining competent performance control in the incidence of interfering 
stimuli and constant monitoring of the external world (MacDonald et al., 
2000; Bunge et al., 2001; Sakai et al., 2002; Lorenz et al., 2003). Correlation 
analysis of functional neuroimaging studies suggest that the dorsolateral 
prefrontal cortex is involved in pain modulation (Iadarola et al., 1998; Baron 
et al., 1999; Bornhovd et al., 2002). Dorsolateral prefrontal cortex stimulation 
using the non-invasive repetitive transcranial magnetic stimulation (rTMS) 
was shown to increase tolerance to human experimental pain (Graff-Guerrero 
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et al., 2005). Other functional neuroimaging studies showed that there was 
increased activity in the prefrontal cortex during anticipation of analgesia with 
placebo treatment (Benedetti et al., 2005; Wager, 2005), and suggest that 
increased prefrontal cortical activity may modulate pain through activation of 
the descending pain inhibitory pathway (Valet et al., 2004; Ohara et al., 2005; 
Xie et al., 2009). In addition, electrical activation of prefrontal cortical fiber 
projections to the midbrain was found to induce antinociceptive effect in 
rodents (Hardy and Haigler, 1985; Zhang et al., 1998). Diffusion tensor 
imaging, a magnetic resonance imaging-based method to allow in vivo 
mapping of the anatomical connections in the human brain showed that tract 
paths could be defined between the PAG and the prefrontal cortex, amygdala, 
thalamus, hypothalamus and rostroventral medial medulla bilaterally 
(Hadjipavlou et al., 2006). In addition, retrograde tracing studies showed that 
the prefrontal cortex sends projections to the PAG mainly from the medial 
prefrontal cortical wall and a few other orbital/anterior insular prefrontal 
cortical regions, suggesting the possible involvement of the prefrontal cortex 
in a top-down modulation of pain through the PAG and subsequent activation 
of the descending pain inhibitory pathway (An et al., 1998; Floyd et al., 2000). 
 
3. Depression and pain 
Depression is defined as an ephemeral mood or emotional state which 
is experienced by almost everyone at some point in life (Fava and Kendler, 
2000). Depression can also be described as a clinical or medical syndrome 
termed as Major Depressive Disorder (MDD) (Fava and Kendler, 2000). MDD 
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is a major health problem which affects mood, cognition, neurovegetative 
activities as well as psychomotor function, and it also causes one of the 
highest levels of non-fatal burden and disability (Fava and Kendler, 2000; 
Chua et al., 2012; Ho et al., 2013). Epidemiological studies show a high 
prevalence of depression worldwide, with 9 % to 20 % of the population 
possibly being affected during their lifetime (Licinio and Wong, 1999; Chua et 
al., 2012). In Singapore, nationwide epidemiological studies in 2003/2004 
showed a 4.9 % prevalence of depression in adults and 3.1 % prevalence in 
elderly populations, while the Singapore National Mental Health Survey in 
2010 revealed that there is a 6.3 % lifetime prevalence of depression in adults 
(Chua et al., 2012). 
The monoamine hypothesis of depression was first suggested in 1965 
and states that depression is caused by a lack of monoamine neurotransmitters 
and function in the brain (Schildkraut, 1965). This theory was supported by 
the mechanism of action of antidepressants which involves increasing the 
levels of monoamine neurotransmitters, predominantly noradrenaline and 
serotonin, and improving depressive symptoms (Delgado, 2000; Hirschfeld, 
2000). However, studies on patients with depression suggest that this 
hypothesis may not be completely accurate and is insufficient to fully explain 
the actions of antidepressants (Delgado, 2000; Hirschfeld, 2000). An 
additional fact is that antidepressant drugs induce their direct biochemical 
effects rather rapidly but their antidepressant effects take weeks to develop 
(Rang et al., 2007). This led to the suggestion that instead of the primary drug 
effects on monoamines in the brain, the clinical improvement of depressive 
symptoms are a result of secondary adaptive responses induced by long-term 
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antidepressant treatment (Rang et al., 2007). Nonetheless, although the 
monoamine hypothesis is inadequate to fully explain depression, drugs 
affecting monoamine levels and functions remain the most effective 
therapeutic method to treat depression. 
Depression is also associated with pain, given that both depression and 
pain symptoms are often found together and are mutually interacting (Bair et 
al., 2003; Williams et al., 2006). Studies showed a higher pain prevalence in 
patients with depression and a higher prevalence of depression in patients 
experiencing pain as compared to individual evaluation of depression and pain 
conditions (Bair et al., 2003). Depression induced a greater number of pain 
grievances and impairment in patients with pain while moderate to severe pain 
is linked to additional symptoms of depression and worse depressive outcomes 
such as reduced work functions (Bair et al., 2003). There are overlying 
neurobiology, biological pathways, therapy and phenomenology linking 
depression and pain (Bair et al., 2003; Williams et al., 2006). This interaction 
has significant implications on treatment and outcome of both depression and 
pain (Bair et al., 2003; Williams et al., 2006). 
 
3.1. Antidepressants  
 In patients with moderate to severe depression, antidepressants are 
generally recommended as the first line of treatment based on recent clinical 
practice guidelines (Chua et al., 2012). Most antidepressants increase the 
levels of monoamine neurotransmitters either by interacting with their 
receptors or affecting their metabolism (Fig. 1.6) (Owens et al., 1997; Coyle 
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and Duman, 2003). Antidepressants generally can be separated into 
monoamine oxidase inhibitors, monoamine reuptake inhibitors and other 
miscellaneous ‘atypical’ antidepressants which have non-selective receptor-
blocking effects and poorly understood mechanisms (Frazer, 1997a; Rang et 
al., 2007).  
Monoamine oxidases (MAOs) are a family of enzymes that are 
involved in the oxidation of monoamines and MAO inhibitors (MAOIs) are 
the first drugs that are used clinically as antidepressants (Edmondson et al., 
2004; Rang et al., 2007). MAO is present in nearly all tissues and there are 
two subtypes of MAO: MAO-A and MAO-B (Pletscher, 1991; Rang et al., 
2007). The main target for MAOIs is the subtype MAO-A which is involved 
in the oxidation of serotonin, noradrenaline and dopamine (Rang et al., 2007). 
MAOIs such as phenelzine and iproniazid generally work by binding 
irreversibly and indiscriminately to both MAO subtypes to inhibit their 
functions (Rang et al., 2007). MAOI were found to have a number of 
undesirable drug and food interactions which could lead to problems such as 
the ‘cheese reaction’ and subsequent acute hypertension (Pletscher, 1991; 
Rang et al., 2007). These unwanted side effects and interactions led to a 
decline in the clinical usage of MAOIs to treat depression. A newer class of 
reversible MAOIs such as moclobemide however, was developed and was 
shown to have fewer interactions and higher specificity for MAO-A compared 
to the older MAOIs (Lotufo-Neto et al., 1999). These new reversible inhibitors 
of monoamine oxidase type A (RIMAs) were suggested to potentially have a 
useful albeit limited role in the differential treatment of depressive disorders 
(Lotufo-Neto et al., 1999). 
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Monoamine reuptake inhibitors act by inhibiting the actions of 
monoamine transporters such as the serotonin transporter.  This will lead to an 
increase in extracellular monoamine neurotransmitter levels and subsequent 
monoaminergic transmission which in turn causes neurochemical changes that 
eventually induce the desired therapeutic effect in the CNS (Richelson, 2003; 
Walter, 2005). Monoamine reuptake inhibitors include selective serotonin 
reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors 
(SNRIs), noradrenaline reuptake inhibitors (NRIs) and tricyclic 
antidepressants (TCAs).  
 
 
Fig. 1.6 Sites of action of antidepressants.   
 
3.2. Pain and antidepressant treatment 
 Inhibitors of cyclooxygenase (COX) enzymes or opioids are used in 
pain conditions such as chronic inflammatory pain. However, long-term usage 
of these drugs is not without problems. Nonselective COX inhibitors may 
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induce gastrointestinal bleeding and kidney damage, while more selective 
COX-2 inhibitors increase cardiovascular disease risk (Mukherjee et al., 
2001). Even though opioids are effective and strong analgesics for acute pain 
treatment, long-term usage may require increasing doses leading to adverse 
effects such as sedation, cognitive disruptions, nausea and constipation (Noble 
et al., 2010). In addition to these serious side effects, major concerns 
surrounding opioid use include the risk of addiction, abuse, misuse and 
diversion.  
On the other hand, there are other drugs such as antidepressants and 
anticonvulsants which have attracted attention as alternative medication for 
pain (Lynch and Watson, 2006). Antidepressants have been observed to 
induce a distinct effect on pain. The dose to modulate pain are mostly found to 
be lower than the dose needed to treat depression and the onset of activity has 
also been shown to be faster (Ryder and Stannard, 2005). In addition, 
antidepressants are analgesic even in non-depressed patients with chronic pain 
and they are also shown to be effective in experimental and acute pain (Ryder 
and Stannard, 2005; Mico et al., 2006). Clinical studies on antidepressants 
found them to be effective in chronic pain conditions such as chronic lower 
back pain (Fishbain, 2000; Salerno et al., 2002; Staiger et al., 2003). 
Neuropathic pain was found to be most responsive to the analgesic and 
antinociceptive effects of antidepressants, whereas TCAs were shown to have 
the greatest analgesic efficacy in several different studies (Finnerup et al., 
2005; Mico et al., 2006).  
Antidepressant-induced antinociception is thought to be linked to the 
central inhibition of monoamine neurotransmitters reuptake, in particular 
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noradrenaline and serotonin, in the CNS (Jasmin et al., 2003; Ryder and 
Stannard, 2005). Besides inducing monoaminergic effects in other parts of the 
CNS, monoamine reuptake inhibition may also lead to increased monoamine 
levels and activity in the synapse which may stimulate descending inhibitory 
action in the spinal cord and affect nociceptive processing. (Jasmin et al., 
2003; Ryder and Stannard, 2005). Formalin tests in rats treated with 
antidepressants and monoamine receptors antagonists indicate that alpha-1 
adrenergic receptors and serotonin receptors in the brain have an important 
role in antidepressant-induced antinociception (Yokogawa et al., 2002). It was 
also suggested that functional interactions between serotonergic and 
noradrenergic neurons in the brain are involved in the antinociceptive effects 
of antidepressants (Yokogawa et al., 2002).  
Nevertheless, there is still a large gap in the knowledge of the actual 
mechanism in which antidepressants exert their antinociceptive effect. It has 
been shown that blockade of monoamine reuptake and subsequent increase in 
monoamine levels may not be the only mechanism involved as the 
antinociceptive effect of the antidepressant, fluvoxamine, was reliant on ATP-
dependent potassium channels activation (Hajhashemi and Amin, 2011) Thus, 
it is possible that the therapeutic effects of antidepressants not only involve the 
inhibition of monoamine neurotransmitters such as serotonin or noradrenaline, 
but also include other mechanisms and potential adaptive cellular changes 
caused by antidepressant treatment.  
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3.3. Tricyclic antidepressants 
 Tricyclic antidepressants (TCAs) are a group of heterocyclic chemical 
compounds that are used as antidepressants. TCAs contain three rings of 
atoms in their molecular structure which they are named after. A closely-
related group of antidepressant compounds are the tetracyclic antidepressants 
which contain four rings of atoms.  Psychopharmacological characterization of 
a series of structural analogs of phenothiazines that were being developed as 
potential antihistamines, sedatives, and analgesic drugs led to the initial 
development of the TCAs (Hollister, 1981; Baldessarini, 2006).  
One of the first few TCAs is a dibenzazepine analog, imipramine, 
which was shown to be ineffective in schizophrenia but had a notable effect in 
patients with depression (Kuhn, 1958). Subsequent findings on the 
effectiveness of imipramine in treating major depression led to the synthesis of 
other chemically related compounds such as desipramine and clomipramine 
(Thase and Perel, 1982; Potter et al., 1998; Baldessarini, 2006). Desipramine 
is the main active metabolite and secondary-amine congener of imipramine 
while clomipramine is its 3-chloro derivative (Baldessarini, 2006). In addition, 
there were also other similar compounds developed which include 
dibenzocycloheptadienes such as amitriptyline and its N-demethylated 
metabolite nortriptyline, along with the dibenzoxepine, doxepin and the 
dibenzocycloheptatriene protriptyline (Baldessarini, 2006). Other analogs 
include the tetracyclic antidepressant, maprotiline, which has an extra ethylene 
bridge across the central six-carbon ring, and amoxapine which is a 
piperazinyldibenzoxazepine with combined neuroleptic and antidepressant 
effects (Baldessarini, 2006). All these analogs possess the three-ring molecular 
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core and most have similar clinical and pharmacological properties 
(Baldessarini, 2006). They are thus collectively termed as “tricyclic 
antidepressants”. 
Antidepressants generally have a relatively good absorption rate after 
oral administration and the serum levels of most TCAs peak within a few 
hours (Baldessarini, 2006; Rang et al., 2007). TCAs are extensively distributed 
in the body once they are absorbed as they are rather lipophilic and can bind 
strongly to plasma albumin (Baldessarini, 2006; Rang et al., 2007). Most 
TCAs are bound up to 90-95 % at therapeutic plasma levels and they bind to 
extravascular tissue which contribute to their low elimination rate and high 
distribution capacity (Rang et al., 2007). However, TCAs and their relatively 
cardiotoxic metabolites tend to accumulate in the cardiac tissue of the heart 
which increase their cardiotoxic risks (Pollock and Perel, 1989; Prouty and 
Anderson, 1990; Wilens et al., 1992). Serum levels of TCAs higher than 500 
ng/ml can cause toxic effects while concentrations higher than 1 µg/ml can be 
lethal (van Harten, 1993; Catterson et al., 1997; Preskorn, 1998). TCAs are 
metabolized via oxidation by microsomal cytochrome P450 (CYP) enzymes  
in the liver followed by conjugation with glucuronic acid (Baldessarini, 2006). 
There are several preferred CYP enzymes for the metabolism of TCAs which 
include CYP1A2, CYP2D6, CYP2C19 and CYP3A3/4 (Table 1.2) 
(Baldessarini, 2006; Mays, 2006). CYP1A2 and CYP2D6 are generally 
involved in aromatic hydroxylation while CYP3A3/4 are essential for the N-
oxidation and N-dealkylation reactions (Baldessarini, 2006). Preferential 
oxidation of TCAs occurs at different positions depending on the 
antidepressant involved (Baldessarini, 2006). For example, oxidation of 
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imipramine and desipramine takes place at the 2-position while oxidation of 
amitriptyline and nortriptyline occurs at the 10-position (Baldessarini, 2006). 
The 10-hydroxy metabolites of amitriptyline and nortriptyline were found to 
be less cardiotoxic than the 2-hydroxy metabolites of imipramine and 
desipramine (Pollock and Perel, 1989; Baldessarini, 2006). Any residual 
biological activity of these metabolites are generally quenched by conjugation 
with glucuronic acid and subsequently excreted in the urine (Baldessarini, 
2006; Rang et al., 2007). It is noted that the N-methylated derivatives of a few 
TCAs still possess pharmacological activity and could potentially affect their 
pharmacodynamics if they accumulate to levels close to or more than the 
parent drug (Baldessarini, 2006). Metabolism and excretion generally take 
place over several days and most TCAs are almost entirely eliminated within a 
week (Baldessarini, 2006). However, there are a few exceptions in which the 
elimination half-life of the N-methylated metabolites of SSRIs and most 
secondary-amine TCAs are around twice that of the parent drugs (van Harten, 
1993; Baldessarini, 2006). 
 As mentioned earlier, the main mechanism of action of TCAs is to 
block the reuptake of monoamine neurotransmitters at the nerve terminals 
(Rang et al., 2007). They do so by competitive inhibition of the binding site of 
monoamine neurotransmitter transporter protein (Rang et al., 2007). TCAs 
generally do not directly affect the synthesis, storage and release of 
monoamine transmitters but some TCAs were found to block presynaptic 
alpha-2 adrenergic receptors and indirectly increase the release of 
noradrenaline (Rang et al., 2007). Most TCAs inhibit the noradrenaline and 
serotonin transporters while having much fewer effect on the dopamine 
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transporters (Richelson, 1996; Frazer, 1997b; Owens et al., 1997; Leonard and 
Richelson, 2000). It was postulated that the TCA-induced increase in 
serotoninergic transmission improves emotional indications while the increase 
in noradrenergic transmission modulates the biological symptoms of 
depression (Rang et al., 2007). Nonetheless, elucidation of the actual effects of 
TCAs continue to be challenging as the pharmacological activities of the main 
derivatives of TCAs are frequently different from the parent drug (Rang et al., 
2007). Besides affecting the monoamine neurotransmitter transporter, most 
TCAs also interact with other receptors such as histamine receptors and 
muscarinic acetylcholine receptors which also contribute to their various 
adverse effects (Frazer, 1997b; Leonard and Richelson, 2000). 
 Antidepressants commonly have significant side effects and TCAs 
predominantly induce adverse autonomic responses due to their relatively 
potent anti-muscarinic properties (Baldessarini, 2006; Rang et al., 2007). 
Atropine-like effects of TCAs include blurred vision, dry mouth, epigastric 
distress, constipation, palpitations, urinary retention and dizziness whereas 
cardiovascular effects include sinus tachycardia and orthostatic hypotension 
(Baldessarini, 2006; Rang et al., 2007). Other unwanted effects include 
postural hypertension, weakness, fatigue and sedation (Baldessarini, 2006; 
Rang et al., 2007). Interaction with other drugs also increases the probability 
of TCA-induced adverse effects. TCAs were found to interact with a number 
of antihypertensive drugs and potentiate the effects of alcohol (Rang et al., 
2007). In addition, drugs competing to bind to plasma proteins such as aspirin 
will increase the effects of TCA (Rang et al., 2007).  
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 TCAs were the main drugs used in depression treatment until the later 
development of SSRIs (Baldessarini, 2006). Besides treating depression, 
TCAs have been used in treatment of pain. TCAs, together with 
anticonvulsants, are considered to be first-line drugs for the treatment of 
neuropathic pain (Mico et al., 2006). However, as stated previously, the exact 
mechanisms involved in the antinociceptive effects of TCAs especially in 
nociceptive pain remain unclear. 
 
3.3.1. Amitriptyline 
Amitriptyline is one of the first ‘reference’ TCAs and is sold under 
brand names such as Elavil and Enovil (Fig. 1.7) (Mays, 2006). Even though it 
has been more than 50 years since amitriptyline was synthesized and approved 
in 1961, it was found to have at least equal or better efficacy against 
depression as compared to the newer classes of antidepressants such as SSRIs 
and is still commonly used (Barbui and Hotopf, 2001; Fangmann et al., 2008). 
Amitriptyline is predominantly a SNRI with strong effects on the serotonin 
transporter and weaker effects on the noradrenaline transporter (Table 1.2) 
(Frazer, 1997b; Owens et al., 1997; Tatsumi et al., 1997; Leonard and 
Richelson, 2000). It has very weak effects on the dopamine transporter and, 
thus, does not affect the reuptake of dopamine (Frazer, 1997b; Tatsumi et al., 
1997).  
Besides treating depression, amitriptyline is used for conditions such as 
attention-deficit hyperactivity disorder (ADHD), tension headache and post-
traumatic stress disorder (Lance and Curran, 1964; Davidson et al., 1990; 
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Banaschewski et al., 2004). Amitriptyline is also effective in modulating pain 
and symptoms in conditions such as post-herpetic neuralgia, diabetic 
neuropathy pain and ankylosing spondylitis (Watson et al., 1982; Max et al., 
1987; Koh et al., 1997). In addition, amitriptyline was shown to have analgesic 
activity in a mouse model of acute pain and a dose-response analgesic effect in 
chronic pain in human patients (McQuay et al., 1993; Paudel et al., 2007). 
Amitriptyline is also commonly used for treatment of chronic neuropathic pain 
and fibromyalgia (Moore et al., 2012). 
Patients taking amitriptyline have an increased risk for suicide and they 
need to be observed and monitored for clinical deterioration and suicidal 
tendencies (Murinson, 2013). Other side effects of amitriptyline include dry 
mouth and sedation (Baldessarini, 2006). Sedation caused by amitriptyline, 
however, can be used to provide greater relief and better sleep especially in 
patients who experience higher pain severity in the evening or at night 
(Nishishinya et al., 2008; Murinson, 2013).  
 
 
Fig. 1.7 Amitriptyline structure. Adapted from (Baldessarini, 2006) 
 




 Nortriptyline is a second generation TCA sold under brand names such 
as Aventyl and Pamelor (Fig. 1.8) (Mays, 2006). Nortriptyline is the active N-
demethylated metabolite of amitriptyline and is similar to amitriptyline 
(Baldessarini, 2006). Nortriptyline functions as a SNRI with weak effects on 
the dopamine transporter (Baldessarini, 2006). However, nortriptyline has 
much stronger effects on the noradrenaline transporter and weaker effects on 
the serotonin transporter as compared to amitriptyline (Table 1.2) (Frazer, 
1997b; Owens et al., 1997; Leonard and Richelson, 2000). Nortriptyline is 
also more selective for the inhibition of noradrenaline reuptake compared to 
amitriptyline (Fig. 1.10) (Baldessarini, 2006; Rang et al., 2007). 
 Nortriptyline is FDA-approved for the treatment of symptoms of MDD 
and besides treating depression, nortriptyline is also used in treatment of 
ADHD and irritable bowel syndrome (Wilens et al., 1993; Clouse, 2003; 
Murinson, 2013). In addition, nortriptyline has been shown to be effective in 
management for pain conditions such as chronic low back pain and is 
commonly used by pain specialists (Atkinson et al., 1998; Murinson, 2013). 
Nortriptyline showed comparable efficacy to morphine in post-herpetic 
neuralgia and has been found to have at least equal efficacy as gabapentin in 
treatment of diabetic polyneuropathy (Raja et al., 2002; Gilron et al., 2009). 
Furthermore, treatment with both nortriptyline and gabapentin led to better 
pain relief in patients (Gilron et al., 2009). 
 Similar to amitriptyline, patients treated with nortriptyline need to be 
monitored for clinical worsening and suicidal inclinations (Murinson, 2013). 
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However, the incidence of side effects associated with nortriptyline is lower 
compared to amitriptyline (Baldessarini, 2006; Mays, 2006). Nortriptyline also 
has lower sedating effects than amitriptyline (Murinson, 2013). 
 
 
Fig. 1.8 Nortriptyline structure. Adapted from (Baldessarini, 2006) 
 
3.3.3. Maprotiline 
Maprotiline is a tetracyclic antidepressant with an extra ethylene 
bridge across the central six-carbon ring (Fig. 1.9). It is pharmacologically 
related to the TCAs and is, thus, also termed as a “tricyclic antidepressant”. .It 
is sold under brand names such as Ludiomil and Psymion (Kessell and Holt, 
1975; Baldessarini, 2006). Maprotiline primarily functions as a strong 
inhibitor of noradrenaline reuptake with robust effects on the noradrenaline 
transporter and much weaker effects on the serotonin and dopamine 
transporter (Table 1.2) (Baldessarini, 2006; Rang et al., 2007). Maprotiline has 
a higher selectivity for noradrenaline reuptake inhibition compared to both 
amitriptyline and nortriptyline (Fig. 1.10) (Rang et al., 2007). 
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Maprotiline is effective in treating different forms and severity of 
depression such as depressive neurosis (Kessell and Holt, 1975; Pinder et al., 
1977). Studies also showed that maprotiline is effective in the treatment of 
chronic pain, chronic tension headache, painful polyneuropathy and chronic 
lower back pain (Fogelholm and Murros, 1985; Lindsay and Olsen, 1985; 
Vrethem et al., 1997; Atkinson et al., 1999). In addition, long-term combined 
treatment of maprotiline and diazepam significantly reduced the symptoms 
and signs of TMD (Ivkovic et al., 2008). Maprotiline was shown to be 
effective in post-herpetic neuralgia as well (Watson et al., 1992).  
Maprotiline has comparable side effects as the other TCAs which 
include dry mouth, dizziness and constipation (d'Elia et al., 1981; Vaz-Serra et 
al., 1994; Baldessarini, 2006). Similar to amitriptyline and nortriptyline, 
maprotiline treatment was found to increase the risk of suicidal tendencies 
(Pinder et al., 1977). Adverse skin reactions occurred more frequently with 
maprotiline treatment (Pinder et al., 1977). However, results from controlled 
trials showed that there are very few differences between maprotiline and 
amitriptyline in the general incidence and severity of adverse effects (Pinder et 
al., 1977). Nonetheless, maprotiline has been reported to have a higher risk of 
causing seizures than the other TCAs (Skowron and Stimmel, 1992; 
Baldessarini, 2006). 
The antidepressive effect of maprotiline was found to involve the 
phospholipase A2 enzyme, iPLA2, in the prefrontal cortex (Lee et al., 2012). 
Maprotiline treatment caused a significant increase in lysophosphatidylcholine 
levels coupled with a decrease in phosphatidylcholine levels, signifying 
increased PLA2 activity and endogenous release of long chain polyunsaturated 
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fatty acids (Lee et al., 2012). Inhibition of iPLA2 in the prefrontal cortex 
eliminated the change in lipid profile and abolished the antidepressive effect 
of maprotiline in a mouse forced swim test model of depression (Lee et al., 
2012). The results suggest that prefrontal cortical iPLA2 has an essential role 
in the antidepressive effect of maprotiline, potentially via the release and 
activity of long chain PUFAs (Lee et al., 2012). Thus, it is possible that the 
expression and activity of iPLA2 in the prefrontal may also have a role in the 
antinociceptive effect of maprotiline. 
 
 
Fig. 1.9 Maprotiline structure. Adapted from (Baldessarini, 2006) 
 




Fig. 1.10 Selectivity for inhibition of noradrenaline reuptake by several TCAs. 
Adapted from (Rang et al., 2007) 
 




Table 1.2 Potencies and elimination profile of amitriptyline, nortriptyline and maprotiline based on radioactive ligand transport competition 
assays. Adapted from (Frazer, 1997b; Owens et al., 1997; Leonard and Richelson, 2000; Baldessarini, 2006). 
Drug 
























Amitriptyline 34.5 4.33 3200 16 30 100 – 250 
2D6, 2C19, 
3A3/4 
Nortriptyline 4.35 18.5 1140 30 - 60 – 150 
2D6, 2C19, 
3A3/4 
Maprotiline 11.1 5900 1000 48 - 200 – 400 
2D6, 2C19, 
3A3/4 
1 Potency is expressed as inhibition constant (Ki) in nanomoles.
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Aims of Study 
 Clinical studies found that certain classes of antidepressants are 
effective in the management of pain conditions including lower back pain, 
migraine, tension headache, atypical facial pain and chronic orofacial pain 
(Lynch and Watson, 2006). However, the biological substrates through which 
antidepressants exert their effects are largely unknown. Studies found that 
antidepressants that are effective in antinociception are most commonly those 
that act on the noradrenergic system, or noradrenergic and serotoninergic 
system, whereas those that act solely on the serotoninergic system are 
generally less effective (Sansone and Sansone, 2008; Verdu et al., 2008).  
At the supraspinal level, the prefrontal cortex has been shown to be 
involved in antinociception and may also be affected by antidepressant 
treatment. The frontal cortex is richly innervated by aminergic fibers (Jordan 
et al., 1994; Carvalho et al., 2005), and is activated in acute and chronic pain 
(Peyron et al., 2000; Maihofner et al., 2004; Maihofner and Handwerker, 
2005). Antinociception in rodents was found to involve electrical stimulation 
of prefrontal cortical fiber connections to the midbrain (Hardy and Haigler, 
1985; Zhang et al., 1998). 
Our recent study revealed an important role of prefrontal cortical 
iPLA2 in the effectiveness of maprotiline to treat depression (Lee et al., 2012). 
Besides treating depression, maprotiline was also shown to induce an 
antinociceptive effect in pain conditions, including chronic lower back pain 
and TMD (Atkinson et al., 1999; Ivkovic et al., 2008). Thus, the present study 
was carried out with three main aims in mind. The first main aim is to study a 
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possible role of prefrontal cortical iPLA2 in the antinociceptive effect of 
maprotiline and another TCA, amitriptyline. Secondly, we would like to 
investigate the effect of antidepressant treatment on iPLA2 expression and 
determine the possible mechanisms involved in iPLA2 expression. The third 
and final aim of this study is to examine the effect of antidepressant treatment 
on 15-LOX which metabolizes DHA to generate docosanoids such as 
resolvins (Farooqui, 2011). It is hoped that our results could provide insights 
into the brain regions involved in supraspinal antinociception as well as 
possible cellular mechanisms involved in iPLA2 expression and the 
antinociceptive effect of antidepressants. 
  










Chapter 3: Role of Prefrontal Cortical iPLA2 in 
Antidepressant-Induced Antinociception 
  





The prefrontal cortex is part of the cerebral cortex which encompasses 
the anterior portion of the frontal lobe and includes Brodmann areas 9, 10, 11, 
12, 46 and 47 (Fuster, 2008). In addition to playing an important role in 
executive functions, the prefrontal cortex has been shown to be involved in 
antinociception by correlation analysis of functional neuroimaging studies 
(Iadarola et al., 1998; Baron et al., 1999; Bornhovd et al., 2002). Activation of 
the dorsolateral prefrontal cortex by rTMS activation also increased pain 
tolerance in human experimental pain studies (Graff-Guerrero et al., 2005). 
Studies suggest that increased prefrontal cortical activity may modulate pain 
through projections to the midbrain to stimulate PAG and subsequent 
activation of the descending pain inhibitory pathway (Hardy and Haigler, 
1985; Valet et al., 2004; Ohara et al., 2005; Xie et al., 2009). Similar to the 
brainstem and spinal cord, there are high levels of aminergic neurons and 
fibers in the prefrontal cortex (Jordan et al., 1994; Carvalho et al., 2005). 
Thus, the prefrontal cortex may also be affected by changes in the monoamine 
neurotransmitter levels after antidepressant treatment. 
Antidepressants such as TCAs have been shown to be effective in the 
management of pain (Lynch and Watson, 2006). However, the biological 
substrates and the mechanisms involved in antidepressant-induced 
antinociception remain largely unknown. Our recent study showed an 
important role of prefrontal cortical iPLA2 in the hippocampo-prefrontal 
cortical LTP and spatial working memory as well as in the antidepressive 
effect of maprotiline (Lee et al., 2012; Shalini et al., 2014). Besides its 




antidepressive effects, maprotiline was also shown to possess antinociceptive 
properties in pain conditions such as TMD (Atkinson et al., 1999; Ivkovic et 
al., 2008). Thus, it is possible that prefrontal cortical iPLA2 may similarly 
have an essential role in the antinociceptive effect of maprotiline and other 
similar antidepressants. In this part of the study, we investigated a possible 
role of prefrontal cortical iPLA2 in the antinociceptive effect of maprotiline 
and another TCA, amitriptyline, using a carrageenan mouse model of 
inflammatory orofacial pain (Yeo et al., 2004; Poh et al., 2012). We also 
studied the effects of maprotiline treatment on prefrontal cortical iPLA2 
expression and the lipid profile of the prefrontal cortex. 
Pain behavioral assay was first carried out to examine the potential 
antinociceptive effect of antidepressant treatment on pain responses and 
whether knockdown of prefrontal cortical iPLA2 will affect the observed pain 
responses. The antinociceptive effect of maprotiline treatment was shown to 
be modulated by prefrontal cortical iPLA2 knockdown. Another set of pain 
behavioral assay was then carried out after iPLA2 knockdown at the 
somatosensory cortex to examine whether the effects of iPLA2 knockdown on 
maprotiline treatment is specific to the prefrontal cortex. Real-time RT-PCR 
and Western blot analyses were performed to investigate the effect of 
maprotiline treatment on iPLA2, specifically iPLA2β, which is involved in 
brain DHA signaling and metabolism (Basselin et al., 2010). Western blot 
analysis was also carried out to validate the efficacy of iPLA2 antisense 
oligonucleotide and this was followed by lipidomic analysis to study the 
effects of maprotiline treatment and iPLA2 knockdown on the lipid profile of 
the prefrontal cortex. 





2. Materials and methods 
2.1. Experimental animals 
A total of 80 male C57BL mice weighing between 20 – 30 g each and 
around 6 – 8 weeks old were used throughout this study. They were obtained 
from NUS Comparative Medicine Animal Facility and were housed under 
defined conditions (65 % relative humidity, 22 °C room temperature and 12 
hours of lighting daily) with unrestricted access to water and food. All mice 
were randomized to treatment and all animal procedures were carried out in 
accordance to the approval and guidelines of the Institutional Animal Care and 
Use Committee of NUS. 
 
2.2. Pain behavioral studies 
2.2.1 Effect of antidepressant and oligonucleotide treatment on pain 
behavioral responses 
Pain behavioral studies were first carried out to study the effect of 
antidepressant treatment and iPLA2 knockdown on pain behavioral responses 
in a mouse model of inflammatory orofacial pain. There were two parts for the 
pain behavioral studies where the first part involved intracortical 
oligonucleotide injections at the dorsolateral prefrontal cortex while the 
second part involved oligonucleotide injections at the somatosensory cortex.  
For the first part of the pain behavioral studies involving intracortical 
(i.c.) injections at the dorsolateral prefrontal cortex, mice were divided into 




seven equal groups (six mice per group) and given daily intraperitoneal (i.p.) 
injections of maprotiline (two groups), amitriptyline (two groups) or saline 
(three groups) throughout the duration of the study (Fig. 3.1). For maprotiline 
treatment, the chosen dose of 10 mg/kg was based on previous studies which 
showed both behavioral and neurochemical changes in animal models after 
maprotiline administration (Parra et al., 2000; Tan et al., 2006; Lee et al., 
2012). A dose of 10 mg/kg was likewise chosen for amitriptyline based on 
previous pain studies (Paudel et al., 2007). For the second part of the study 
involving somatosensory cortex (s.s.) injection, three groups of mice (six mice 
per group) were given daily i.p. maprotiline (two groups) or saline (one group) 
injections throughout the duration of the study (Fig. 3.1). Only one saline 
treatment group was used in the second part of the study as a baseline pain 
reference for comparison to the maprotiline treated groups after 
oligonucleotide injections at the somatosensory cortex and also to reduce the 
number of necessary animals used as accordance to the Institutional Animal 
Care and Use Committee of NUS guidelines. Our previous study had shown 
that the number of six mice per group was sufficient to display significant 













Fig. 3.1 Schematic flowchart of the experimental outline and animal grouping 
for the pain behavioral studies. 
 
2.2.2 Dorsolateral prefrontal cortex intracortical (i.c.) oligonucleotide injection 
On day 21 of maprotiline, amitriptyline or saline treatment, mice were 
anesthetized by i.p. injection of ketamine/medetomidine mixture and 




positioned on a stereotaxic device (Stoelting, USA). Dorsolateral prefrontal 
cortex intracortical (i.c.) oligonucleotide injections were carried out one hour 
after maprotiline, amitriptyline or saline treatment. Antisense oligonucleotide 
(3 µg/µl), sense oligonucleotide (3 µg/µl) or sterile saline was stereotaxically 
administered into the right and left sides of the dorsolateral prefrontal cortex 
through small craniotomies on the skull (coordinates: 2.5 mm rostral to 
bregma, 1.5 mm lateral to midline and 1.5 mm from surface of cortex). A total 
volume of 1 µl was injected over 5 minutes on each side and the scalp was 
sutured after the injection was done. The antisense oligonucleotide used was a 
20-base oligonucleotide which corresponds to nucleotides 59–78 of the murine 
iPLA2 sequence (5’-CTCCTTCACCCGGAATGGGT-3’) and was shown to 
reduce iPLA2 expression in mouse P388D1 macrophage-like cells (Balsinde et 
al., 1997). Our previous study also showed the effectiveness of the iPLA2 
antisense oligonucleotide in decreasing iPLA2 expression in the mouse 
prefrontal cortex (Lee et al., 2012). Scrambled sense oligonucleotide was used 
as a control (5’-ACCCATTCCGGGTAAAGGAG-3’). Both antisense and 
sense oligonucleotides contained phosphorothioate linkages to prevent 
nuclease degradation.  
 
2.2.3. Somatosensory cortex (s.s.) oligonucleotide injection 
The procedures and timeline for somatosensory cortex oligonucleotide 
injections were similar to that of the prefrontal cortex injections, except that 
maprotiline or saline treated groups received sense or antisense 
oligonucleotides or saline in the somatosensory cortex at coordinates: 1.5 mm 




caudal to bregma, 3 mm lateral to the midline and 1.5 mm from the surface of 
the cerebral cortex.  
 
2.2.4. Facial carrageenan injection and pain behavioral assay 
On day 24 of antidepressant or saline treatment, mice were first 
anesthetized and subsequently injected with 50 µL carrageenan (2 mg/50 µL 
of lambda carrageenan) in the subcutaneous tissue over the left maxillary, 
ophthalmic and mandibular region. Carrageenan administration resulted in a 
constant swelling of approximately 4 mm in diameter and induced allodynia in 
the days following the injection as shown in our previous study (Poh et al., 
2012). Mice were tested for pain behavioral responses before carrageenan 
injection, and once daily after carrageenan injection at one hour after daily 
antidepressant or saline i.p. treatment. Testing of pain behavioral responses 
was performed in a blinded manner and was carried out individually in a deep 
rectangular tank, sized (L x W x H) 60 × 40 × 25 cm (Vos et al., 1994; Poh et 
al., 2009). A von Frey hair filament (Touch-Test Sensory Evaluator, North 
Coast Medical, Morgan Hill, USA) delivering 1.4 g force (4.17 log units = 
13.725 mN) was used to test the pain behavioral responses. The von Frey hair 
was first reached into the tank for 5 – 10 minutes to ensure that the mice were 
familiarized with the reaching movements before testing. Mice were observed 
to confirm that they were able to move without restrictions during this period 
of time. Test stimuli using the von Frey hair was administered when the mice 
were neither freezing nor moving and with all four paws placed on the ground 
while displaying sniffing behavior. To acquire an adequate number of 




responses for the reduction of variability among individual mice in each 
treatment group, the carrageenan-injected area of the face was probed 20 times 
with the von Frey hair. Each new stimulus with the von Frey hair was 
administered at least 30 seconds after the previous administration. Directed 
facial grooming (a continuous series of facial wash strokes directed to the 
stimulated facial area by the mice) was utilized as an indicator of unilateral 
facial pain in freely moving mice. The number of immediate asymmetric facial 
grooming/scratching strokes was then obtained to calculate the total number of 
facial strokes displayed by each animal after 20 stimulations using the von 
Frey hair filament. The mean and standard error of total facial strokes were 
calculated and possible significant differences studied using two-way mixed 
ANOVA to analyze the interactions between treatment and time on the mean 
pain behavioral responses, followed by two-tailed Student’s t-tests to compare 
the possible significant differences in the mean pain behavioral responses 
between the different treatment groups at each time point (IBM SPSS 
Statistics, Version 20.0, New York, USA). P < 0.05 was considered 
significant. 
 
2.3. Effect of maprotiline treatment on iPLA2 mRNA and protein expression 
in the prefrontal cortex 
This part of the study was then carried out to investigate the effect of 
maprotiline treatment on prefrontal cortical iPLA2 mRNA and protein 
expression. Two groups of mice (four mice per group) were given daily i.p. 
injections of either maprotiline (Sigma, St. Louis, USA) or saline for 28 days. 




After 28 days, mice were sacrificed by i.p. injection of 
ketamine/medetomidine cocktail and decapitated, and the prefrontal cortex 
dissected out for subsequent Real-time RT-PCR and Western blot analyses 
(Fig. 3.2).  
 
2.4. Effect of iPLA2 knockdown on iPLA2 protein expression and lipid profile 
The antisense oligonucleotide to iPLA2 being used in this study was 
previously shown to successfully knockdown iPLA2 expression in the normal 
mouse prefrontal cortex (Lee et al., 2012). Thus, this part of the study was 
carried out to further validate the efficacy of this antisense oligonucleotide to 
similarly reduce iPLA2 levels in maprotiline-treated mice using Western blot 
analysis. Lipidomic analysis was also performed to study the effects of 
maprotiline treatment and iPLA2 knockdown on the lipid profile of the 
prefrontal cortex (Fig. 3.2). Three groups of mice (four mice per group) were 
given daily i.p. injections of either maprotiline (two groups) or saline (one 
group). On day 21 of i.p. injection, saline-treated mice received intracortical 
injection of normal saline to the prefrontal cortex, while one group of 
maprotiline-treated mice was intracortically injected with iPLA2 antisense 
oligonucleotide, and the other with scrambled sense oligonucleotide. Facial 
carrageenan injection was then administered to the above mice on day 24 of 
i.p. injection. Pain behavioral response testing was carried out daily until the 
time of sacrifice on 4 days after carrageenan injection. The prefrontal cortex 
was harvested for Western blot analysis to verify the efficacy of antisense 
oligonucleotide to iPLA2 and for lipidomic analysis. 






Fig. 3.2 Schematic flowchart of the experimental outline and animal grouping 
for the real-time RT-PCR, Western blot and lipidomic analyses. 





2.5. Real-time RT-PCR 
RNA was extracted from the prefrontal cortex and reverse transcribed 
using High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems, 
CA, USA). The conditions for the reverse transcription reactions were 25 °C 
for 10 minutes followed by 37 °C for 120 minutes and 85 °C for 5 minutes. 
Quantitative real-time PCR amplification was then performed in the 7500 
Real-time PCR system (Applied Biosystems, CA, USA) using the converted 
cDNA together with TaqMan® Universal PCR Master Mix (Applied 
Biosystems, CA, USA) and TaqMan® probes for mouse iPLA2β and beta-actin 
(Mm01299491_m1 and #4331182 respectively, synthesized by Applied 
Biosystems). The conditions for real-time PCR amplification were initial 
incubation at 50 °C for 2 minutes and 95 °C for 10 minutes, followed by 40 
cycles of 95 °C for 15 seconds and 60 °C for 1 minute. All amplification 
reactions were carried out in triplicates. The number of reaction cycles at 
which the reporter fluorescence emission exceeds the preset threshold level is 
the threshold cycle, CT. There is an inverse correlation between the CT value 
and the levels of target mRNA. The amplified transcripts were then quantified 
using the comparative CT method with the formula for relative fold change = 
2−∆∆CT (Livak and Schmittgen, 2001).  The mean and standard error for each 
treatment group were calculated and possible significant differences analyzed 
using two-tailed Student’s t-test. P < 0.05 was considered significant. 
 
 





2.6 Western blot analysis 
Proteins were first extracted from the prefrontal cortex using T-PER® 
Tissue Protein Extraction solution containing 1 % HaltTM protease inhibitor 
and 1 % EDTA solution (Thermo Fischer Scientific, Rockford, IL, USA). 
Concentrations of the protein obtained were measured using the Bio-Rad 
protein assay kit. Protein samples (30 µg) were then mixed with a loading dye 
consisting of SDS and DTT before undergoing denaturation at 95 – 100 °C for 
10 minutes and resolved in 10 % SDS-polyacrylamide gels under reducing 
conditions. A protein ladder containing molecular weight of 250, 150, 100, 75, 
50, 37, 25, 20, 15 and 10 kDa was also used to monitor the electrophoresis run 
and to check for protein size as well as protein transfer efficacy (Precision 
Plus Protein Dual Color Standards, Bio-Rad Laboratories, CA, USA). The 
resolved proteins were then electrotransferred to a polyvinylidene difluoride 
(PVDF) membrane and non-specific binding sites were blocked by incubation 
for 1 hour with 5 % non-fat milk in tris-buffered saline containing 0.1 % 
Tween-20 (TBST). After blocking, the PVDF membrane was incubated 
overnight with iPLA2 antibody (#sc-14463, Santa Cruz Biotechnology, CA, 
USA; diluted 1:2000 in 5 % non-fat milk in TBST) at 4 C. The PVDF 
membrane was then washed with TBST and incubated with horseradish 
peroxidase-conjugated anti-goat IgG (Thermo Fisher Scientific, Rockford, IL, 
USA; diluted 1:2000 in 5 % non-fat milk in TBST) for 1 hour at room 
temperature. The protein bands were visualized with an enhanced 
chemiluminescence kit (Supersignal West Pico, Thermo Fisher Scientific, 




Rockford, IL, USA). For the loading controls, the membrane was incubated 
with a stripping buffer for 10 minutes at room temperature (Restore Western 
Blot Stripping Buffer, Thermo Fisher Scientific, Rockford, IL, USA). After 
stripping, the membrane was again blocked with 5 % non-fat milk in TBST 
before incubating with a mouse monoclonal antibody to beta-actin (Sigma-
Aldrich, St. Louis, MO, USA; diluted 1:10000 in 5 % non-fat milk in TBST) 
for 1 hour at room temperature. The membrane was then incubated with 
horseradish peroxidase-conjugated anti-mouse IgG (Thermo Fisher Scientific, 
Rockford, IL, USA; diluted 1:10000 in 5 % non-fat milk in TBST) for 1 hour. 
Visualization of the protein bands were then carried out as mentioned earlier. 
Visualized films containing the protein bands were scanned and their densities 
were measured using the Gel-Pro Analyzer 3.1 program (Media Cybernetics, 
Silver Spring, MD, USA). The densities of the target bands were normalized 
against those of beta-actin. The mean and standard error were then calculated 
and possible significant differences analyzed using two-tailed Student’s t-test 
or one-way ANOVA with Bonferroni multiple comparison post-hoc test. P < 
0.05 was considered significant. 
 
2.7. Lipidomic analysis 
Prefrontal cortex tissue samples were homogenized using a sonicator 
for 30 minutes at 4 ºC in 750 μL of chloroform/methanol, 1:2 (v/v) and 5 μL 
of an internal standards solution, containing N-lauroyl-D-erythro-
sphingosylphosphorycholine, N-heptadecanoyl-D-erythro-sphingosine and 
1,2-dimyristoyl-sn-glycero-3-phosphocholine, all from Avanti Polar Lipids 




(Alabaster, AL, USA). Samples were then mixed with 250 μL chloroform and 
450 μL 0.88 % potassium chloride (KCl), vortexed and centrifuged at 9000 g 
at 4 °C for 2 minutes. The aqueous phase was re-extracted with 250 µl of 
chloroform and the extracted organic fractions pooled. Lipids were isolated 
from the organic phase, vacuum-dried (Thermo Savant SpeedVac, USA), and 
resuspended for analyses. An Agilent 1290 UPLC system connected with an 
Agilent 6460 Triple Quadrupole mass spectrometer (Santa Clara, CA, USA) 
was used for quantification of individual polar lipids. The column used was a 
Kinetex HILIC (150 X 2.10 mm) packed with 2.6 µM core-shell particles 
from Phenomenex (Torrance, CA, USA). Solvents used for the HILIC LC: 50 
% acetonitrile in water containing 25 mM ammonium formate pH 4.6 (solvent 
A) and 95 % acetonitrile containing 25 mM ammonium formate H 4.6 (solvent 
B). Analytes were eluted with the following gradient: 0.1 % solvent A and 
99.9 % solvent B from 0 to 6 minutes, 75 % solvent A and 25 % solvent B 
from 6 to 7 minutes, 90 % solvent A and 10 % solvent B from 7 to 7.1 
minutes, and 0.1 % solvent A and 99.9 % solvent B from 7.1 to 10.1 minutes 
with a constant flow rate of 0.5 mL/minute. MS source parameters: gas 
temperature 300 ºC with a flow of 5 L/minute and nebulizer at 45 psi. Sheath 
gas temperature 250 ºC with a gas flow rate of 11 L/minute. The Agilent 6460 
triple quadrupole was operated in positive mode for Multiple Reaction 
Monitoring (MRM). In the positive ion MRM mode, product ions at 184 m/z 
were monitored after CID of the lipid precursors for both cholines and 
sphingomyelins. Product ions at 262, 264 and 266 m/z were monitored for d18 
ceramides. Quantification was performed according to the internal standard 
method, comparing peak areas of the sample to the ISTD. All samples were 




resuspended in solvent B before injecting the sample for LC-MS analyses. 
Data were extracted and analyzed using Agilent MassHunter Qualitative and 
Agilent MassHunter Quantitative software (Santa Clara, CA, USA). The mean 
and standard error for each lipid species were calculated and then analyzed 
using one way ANOVA with Bonferroni multiple comparison post-hoc test to 
check for possible significant differences. P < 0.05 was considered significant. 
 
3. Results 
3.1. Pain behavioral studies 
3.1.1. Antidepressant and prefrontal cortex oligonucleotide treatment groups 
A higher number of facial strokes indicate more pain and a higher pain 
behavioral response. Responses of the saline + iPLA2 antisense 
oligonucleotide, saline + scrambled sense oligonucleotide and saline + saline 
groups showed a similar trend and all three peaked at day 4 after carrageenan 
injection. Responses of the amitriptyline + antisense and amitriptyline + sense 
treatment groups also showed a similar trend and peaked at day 4 after 
carrageenan injection. Responses of the maprotiline + antisense 
oligonucleotide treatment peaked at day 5 while the maprotiline + sense 
oligonucleotide treatment peaked at day 3 after carrageenan injection. The 
maprotiline + antisense treatment group had a higher trend in pain behavior as 
compared to the maprotiline + sense treatment group. This trend by the 
maprotiline + antisense group was similar to that of the saline treatment 
groups (Fig. 3.3).  




Two-way ANOVA indicated that the within subject effects were 
significant, F(14, 490) = 304.688, P < 0.001. This showed that there was a 
significant interaction between treatment and time on the pain behavioral 
responses. Further two-tailed Student’s t-test carried out to compare between 
the treatment groups showed no significant differences between the saline + 
saline and saline + antisense groups, indicating that antisense iPLA2 treatment 
to the prefrontal cortex in the absence antidepressant treatment did not have 
any effect on pain behavior (Fig. 3.3).  
Similar to that of saline-treated mice, there were no significant 
differences between the two amitriptyline treatment groups throughout the 
duration of the study, which indicate that antisense treatment to the prefrontal 
cortex did not have any effect on the pain behavior of amitriptyline-treated 
mice. However, there were significant differences between both amitriptyline 
treatment groups and all three saline treatment groups from days 4 to 14 after 
carrageenan injection, highlighting the antinociceptive effect of amitriptyline 
treatment (P < 0.05) (Fig. 3.3). 
The maprotiline + sense treatment group had significantly lower pain 
behavioral responses from days 4 to 14 after carrageenan injection as 
compared to all three saline treatment groups (Fig. 3.3). Interestingly, the 
number of responses of maprotiline + antisense treatment group was similar to 
that of the saline treatment groups and had significantly greater responses 
compared to the maprotiline + sense treatment group from days 4 to 12 after 
carrageenan injection (P < 0.05) (Fig. 3.3). Overall, the maprotiline + sense 
treatment group showed a lower trend in the number of facial strokes as 




compared to the other groups. The results indicate that maprotiline exerts an 
antinociceptive effect in the facial carrageenan pain model. Antisense 
oligonucleotide to iPLA2 treatment was found to abolish this antinociceptive 
effect and return the facial stroke values similar to that of saline treatment 
groups. The maprotiline + sense treatment group also showed significantly 
lower number of facial strokes as compared to both amitriptyline treatment 
groups on days 4, 5, 7, 9 and 12 after carrageenan injection which suggest that 
maprotiline treatment has a relatively stronger antinociceptive effect in this 
carrageenan mouse model of inflammatory orofacial pain. 
 
 
Fig. 3.3 Pain behavioral responses – antidepressant treatment and prefrontal 
cortex injection. Responses to von Frey hair stimulation after prefrontal cortex 
injection and facial swelling induced by carrageenan administration in 
addition to daily intraperitoneal injection of maprotiline (10 mg/kg), 
amitriptyline (10mg/kg) or saline. The Y-axis represents number of responses 
to von Frey hair stimulation of the carrageenan-injected areas of the face. Day 
0 refers to the day before carrageenan injection was carried out while Day 1 to 
Day 14 refers to 1 day to 14 days after injection. Asterisks (*) indicate 
significant differences at P < 0.05 between the two amitriptyline treatment 
groups and all three saline treatment groups as well as significant differences 
at P < 0.05 between the maprotiline + sense treatment group and all three 




saline treatment groups. Symbol (#) indicate significant differences at P < 0.05 
between maprotiline + sense treatment group and maprotiline + antisense 
treatment group. Symbol (^) indicate significant differences at P < 0.05 
between maprotiline + sense treatment group and both amitriptyline treatment 
groups. Data represent the mean and standard error of six mice per treatment 
group. 
 
3.1.2. Maprotiline and somatosensory cortex oligonucleotide treatment groups 
Responses of the saline + saline treatment group peaked at day 4 after 
carrageenan injection. Responses of both maprotiline treatment groups showed 
a similar trend and peaked at day 4 after carrageenan injection. Both 
maprotiline treatment groups also showed a lower trend as compared to the 
saline + saline treatment group. Two way ANOVA indicated that the within 
subject effects were significant, F(14, 210) = 110.830, P < 0.001. This showed 
that there was a significant interaction between treatment and time on the pain 
behavioral responses. Further two-tailed Student’s t-test carried out to 
compare the treatment groups at each time point showed significant 
differences between the two maprotiline treated groups and the saline + saline 
group from days 4 to 14 after carrageenan injection, indicating antinociceptive 
effect of maprotiline treatment (P < 0.05). However, in contrast to iPLA2 
antisense oligonucleotide injection in the prefrontal cortex, no significant 
difference was detected between the maprotiline + antisense and maprotiline + 
sense treatment group, after oligonucleotide injection to the somatosensory 
cortex (Fig. 3.4). The results suggest that unlike the prefrontal cortex, 
administration of iPLA2 antisense oligonucleotide to the somatosensory cortex 
did not affect the antinociceptive effect of maprotiline. 
 






Fig. 3.4 Pain behavioral responses - maprotiline treatment and somatosensory 
injection. Responses to von Frey hair stimulation after somatosensory cortex 
oligonucleotide injections and facial swelling induced by carrageenan 
administration in addition to daily intraperitoneal injection of maprotiline (10 
mg/kg) or saline. Asterisks (*) indicate significant differences at P < 0.05 
between the saline + saline group and both maprotiline treatment groups. Data 
represent the mean and standard error of six mice per treatment group. 
 
3.2. Effect of maprotiline treatment on prefrontal cortical iPLA2 expression 
3.2.1. Real-time RT-PCR 
Quantitative real-time RT-PCR using the iPLA2β probe showed a 
significant 1.59 fold increase in iPLA2 mRNA expression in the mouse 
prefrontal cortex after maprotiline treatment for 28 days as compared to saline 
treatment (P < 0.05) (Fig. 3.5). The results indicate that maprotiline treatment 
increased iPLA2 mRNA expression in the prefrontal cortex. 
 
 






Fig. 3.5 Effect of maprotiline treatment on iPLA2 mRNA expression in the 
mouse prefrontal cortex. Real-time RT-PCR analysis on iPLA2 expression in 
the mouse prefrontal cortex after maprotiline treatment. Data represent the 
mean and standard error of four mice per treatment group. Asterisks (*) 
indicate significant differences at P < 0.05 when compared to saline control. 
 
3.2.2. Western blot analysis  
Western blot analysis of the mouse prefrontal cortex showed the 
presence of a band at around 85 kDa which corresponds to the band size of the 
iPLA2 protein. Densitometric analyses of the protein blots showed a 
significant 4.2 fold increase in iPLA2 protein expression in the mouse 
prefrontal cortex after maprotiline treatment for 28 days as compared to saline 
treatment (P < 0.05) (Fig. 3.6). The increase in iPLA2 protein expression is 
consistent with the increase in iPLA2 mRNA expression in the prefrontal 
cortex after maprotiline treatment. 
 







Fig. 3.6 Effect of maprotiline treatment on iPLA2 protein expression in the 
mouse prefrontal cortex. (A) Western blot and (B) densitometric analysis of 
iPLA2 protein expression in the mice prefrontal cortex after antidepressant 
treatment. Asterisks (*) indicate significant differences at P < 0.05 when 
compared to saline control. 
 
3.3. Effects of maprotiline treatment and prefrontal cortical iPLA2 knockdown 
on iPLA2 protein expression and lipid profile 
3.3.1. Pain behavioral responses 
Responses of the maprotiline + antisense group and the saline + saline 
group showed a similar trend up to day 4 after carrageenan injection. 
Responses of the maprotiline + sense group showed a peak at day 3 after 




carrageenan injection similar to the responses in Fig. 3.3 and the responses at 
day 4 was lower compared to the maprotiline + antisense group and the saline 
+ saline group. Two way ANOVA indicated that the within subject effects 
were significant, F(4, 36) = 546.781, P < 0.001. This showed that there was a 
significant interaction between treatment and time on the pain behavioral 
responses. Further two-tailed Student’s t-test carried out to compare between 
the treatment groups at each time point showed a significant difference 
between the maprotiline + antisense treatment group and saline + saline 
treatment group and also between the maprotiline + antisense treatment group 
and the maprotiline + sense treatment group on day 4 (Fig. 3.7) after 
carrageenan injection similar to the results in Fig. 3.3 (P < 0.05). The results in 
Fig 3.7 thus importantly showed the reproducibility of the pain behavioral 
















Fig. 3.7 Pain behavioral responses – maprotiline treatment and prefrontal 
cortex injection. Responses to von Frey hair stimulation after prefrontal cortex 
injection and facial swelling induced by carrageenan administration at up to 
day 4 after carrageenan injection and after daily intraperitoneal injection of 
maprotiline (10 mg/kg). Data represent the mean and standard error of four 
mice per treatment group. Asterisks (*) indicate significant differences at P < 
0.05 when comparing maprotiline + sense treatment group to both saline + 
saline and maprotiline + antisense treatment groups.  
 
3.3.2. Western blot analysis 
Western blot analysis of the mouse prefrontal cortex similarly showed 
the presence of a band at around 85 kDa which corresponds to the band size of 
the iPLA2 protein. Densitometric analyses of the protein blots showed a 
significant 3.0 fold increase in iPLA2 protein expression in the mouse 
prefrontal cortex after maprotiline + sense treatment as compared to the saline 
+ saline treatment (P < 0.05) (Fig. 3.8). This result is consistent with the 
increase in iPLA2 mRNA and protein after maprotiline treatment observed 
earlier. Administration of antisense oligonucleotide to iPLA2 to maprotiline 
treated mice, however, significantly abolished the increase in iPLA2 protein 




expression. Results confirmed the effectiveness of antisense oligonucleotide to 
iPLA2 in reducing iPLA2 protein expression in maprotiline treated mice even 




Fig. 3.8 Effect of oligonucleotide treatment on iPLA2 protein expression in the 
mouse prefrontal cortex after maprotiline treatment. (A) Western blot and (B) 
densitometric analysis on the effect of oligonucleotide treatment on iPLA2 
protein expression in the mouse prefrontal cortex after maprotiline treatment. 








3.3.3. Lipidomic analysis 
 Lipidomic analysis results showed that maprotiline treatment had 
significant effects on several different lipid species which was abolished by 
antisense oligonucleotide to iPLA2 treatment. There was a significant increase 
in the PC 32:0 lipid species after maprotiline + sense treatment as compared to 
the other treatment groups, but concentrations of PC 36:1, PC 36:3, PC 38:3, 
PC 38:5, PC 40:4, PC 40:5 and PC 40:6 were significantly reduced after 
maprotiline + sense treatment (P < 0.05). Treatment with maprotiline + 
antisense abolished the changes in phosphatidylcholine lipid species (Fig. 3.9). 
Concurrently, maprotiline + sense treatment caused a significant increase in 
the LPC 16:0, LPC 18:0, 18:1 and LPC 20:4 species, and these were similarly 
abolished after treatment with antisense oligonucleotide (P < 0.05) (Fig. 3.10). 
The general decrease in PC species levels and the increase in LPC levels 
indicate an increased iPLA2 enzymatic activity as iPLA2 hydrolyzes PCs to 
form LPCs and fatty acids. The fatty acids produced was found to include 
DHA as shown by the decrease in PC 40:6 and the increase in LPC 18:0 to 
release a 22:6 fatty acid which is DHA. Similarly, EPA (20:5) was also one of 
the possible fatty-acid side chain released, based on the decrease of PC 38:5 
and the increase of LPC 18:0. In addition, maprotiline + sense treatment 
induced a significant increase in several ceramide species, including Cer 
d18:1/C20:0, Cer d18:1/C22:0, Cer d18:1/C24:0 and Cer d18:1/C24:1, and 
these were repressed by antisense treatment (P < 0.05) (Fig. 3.11). Maprotiline 
+ sense treatment also increased SM 18/16:0 species as well as decreased SM 
18/20:0 and SM 18/24:1 species levels and these changes were abolished by 
antisense treatment (P < 0.05) (Fig. 3.12). The changes in the ceramide and 








Fig. 3.9 Lipidomic analysis - phosphatidylcholine species. Lipidomic analysis 
of PC species in the mice prefrontal cortex after maprotiline and 
oligonucleotide treatment. Data represent the mean and standard error of four 
mice per treatment group. Asterisks (*) indicate significant differences at P < 















Fig. 3.10 Lipidomic analysis - lysophosphatidylcholine species. Lipidomic 
analyses of LPC species in the mice prefrontal cortex after maprotiline and 
oligonucleotide treatment. Asterisks (*) indicate significant differences at P < 

















Fig. 3.11 Lipidomic analyses - ceramide species. Lipidomic analyses of Cer 
species in the mice prefrontal cortex after maprotiline and oligonucleotide 
treatment. Data represent the mean and standard error of four mice per 
treatment group. Asterisks (*) indicate significant differences at P < 0.05 in 

















Fig. 3.12 Lipidomic analyses - sphingomyelin species. Lipidomic analyses of 
SM species in the mice prefrontal cortex after maprotiline and oligonucleotide 
treatment. Asterisks (*) indicate significant differences at P < 0.05 in the lipid 
concentration of maprotiline + sense compared to all other treatment groups. 
 
4. Discussion 
The present study was carried out to investigate the role of prefrontal 
cortical iPLA2 in the antinociceptive effect of maprotiline and amitriptyline as 
well as to examine the effect of maprotiline treatment on prefrontal cortical 
iPLA2 expression and lipid profile. Pain behavioral studies were first carried 
out to determine the effect of antidepressant treatment on nociception in a 
carrageenan mouse model of inflammatory orofacial pain. Behavioral analysis 
of mice that received daily intraperitoneal saline injection and facial 
carrageenan injection showed no difference in the number of facial strokes 
after intracortical injections of saline, sense oligonucleotide, or antisense 




oligonucleotide to iPLA2 at the prefrontal cortex. A higher number of facial 
strokes indicate more pain and a higher pain behavioral response. Our results 
showed that non-specific effect of iPLA2 knockdown on cortical neurons is 
unlikely, and that inhibition of constitutive prefrontal cortex iPLA2 did not 
have a significant effect on pain behavior. This is consistent with our previous 
findings where inhibition of iPLA2 levels in the prefrontal cortex in the 
absence of antidepressant treatment did not affect despair behavior during the 
forced swim test (Lee et al., 2012).  
Both amitriptyline treatment groups showed significantly lower 
number of facial strokes as compared to the saline treatment groups, 
highlighting the antinociceptive activity of amitriptyline. The observed effect 
of amitriptyline on nociception is consistent with its clinical usage in 
managing pain conditions (Fishbain, 2000; Salerno et al., 2002; Staiger et al., 
2003). Similar to the saline treatment groups, administration of antisense 
oligonucleotide to iPLA2 did not affect the pain behavioral responses of the 
amitriptyline treatment groups. The maprotiline + sense treatment group also 
exhibited antinociceptive activity as demonstrated by the reduced number of 
facial wash strokes after von Frey hair stimulation of the carrageenan-injected 
area as compared to the saline treatment groups. In addition, the maprotiline + 
sense treatment group was found to have significantly lower pain responses as 
compared to the amitriptyline groups at several time points of the study which 
seem to suggest that maprotiline treatment is marginally more effective than 
amitriptyline in modulating nociception in the carrageenan mouse model of 
inflammatory orofacial pain. However, the reduction in facial wash strokes 
induced by maprotiline treatment was abolished when the prefrontal cortex 




was intracortically injected with antisense oligonucleotide to iPLA2, 
suggesting that the loss of this enzyme could impact maprotiline-induced 
antinociception. Interestingly, our results showed that knockdown of 
prefrontal cortical iPLA2 only abolished the antinociceptive effects of 
maprotiline but not amitriptyline, suggesting that unlike amitriptyline, 
maprotiline-induced antinociception is highly dependent on prefrontal cortical 
iPLA2. Both maprotiline and amitriptyline are classified as TCAs 
(Baldessarini, 2006). However, amitriptyline has stronger effects on the 
serotonin transporter and weaker effects on the noradrenaline transporter as 
compared to maprotiline (Owens et al., 1997). Maprotiline also has a much 
higher selectivity for inhibition of noradrenaline reuptake as compared to 
amitriptyline (Rang et al., 2007). Thus, it is possible that the antinociceptive 
activity of other TCAs with similarly strong effects on the noradrenaline 
transporter may also involve prefrontal cortical iPLA2. Additional work, 
however, is needed to further investigate this possibility.   
To investigate whether the role of iPLA2 in antidepressant-induced 
antinociceptive effect is specific to the prefrontal cortex, iPLA2 antisense was 
injected into the somatosensory cortex of maprotiline-treated mice followed 
by pain behavioral analysis. Treatment with maprotiline significantly reduced 
pain behavior in mice compared to saline treatment, but in contrast to the 
prefrontal cortex, no significant differences in pain behavior was detected 
between the maprotiline + antisense and the maprotiline + sense groups after 
somatosensory cortex antisense injection. Results indicate that the effect of 
iPLA2 in antinociception is specific to the prefrontal cortex. These findings are 
consistent with the view that the prefrontal cortex and PAG, rather than the 




somatosensory cortex, is a source of supraspinal antinociception (Sessle et al., 
1976; Christie et al., 1986; Floyd et al., 2000). 
We then studied the effect of maprotiline treatment to confirm that 
maprotiline does indeed affect iPLA2 expression in the prefrontal cortex. Real-
time RT-PCR showed a significant increase in iPLA2 mRNA expression in the 
mouse prefrontal cortex after maprotiline treatment and a similar significant 
increase in iPLA2 protein expression was shown by Western blot analysis. 
This increase in iPLA2 expression is consistent with the up-regulation in 
phospholipase A2 activity in the prefrontal cortex after maprotiline treatment 
as shown in our previous study, suggesting a potentially important role of 
iPLA2 in mediating the pharmacological effects of maprotiline (Lee et al., 
2012). Western blot analysis confirmed the efficacy of antisense 
oligonucleotide to iPLA2 in reducing prefrontal iPLA2 protein expression, as 
shown in our previous study on mice without carrageenan injection (Lee et al., 
2012). In that study, we also demonstrated that administration of iPLA2 
antisense oligonucleotide to the prefrontal cortex did not induce apoptosis in 
the prefrontal cortex (Lee et al., 2012). 
Increased iPLA2 expression in the brain may lead to endogenous 
release of DHA and EPA as shown in our previous study (Lee et al., 2012). 
Similar to our previous study on mice without carrageenan injection (Lee et 
al., 2012), lipidomic analysis of the prefrontal cortex in mice that received 
maprotiline and facial carrageenan injection showed significant increases in 
LPC lipid species and decreases in PC lipid species, suggesting increased 
iPLA2 activity. The fatty-acid side chain released by iPLA2 activity was found 




to include DHA (22:6), based on the decrease of PC 40:6 and the increase of 
LPC 18:0. Similarly, EPA (20:5) was also one of the possible fatty-acid side 
chain released, based on the decrease of PC 38:5 and the increase of LPC 18:0. 
DHA is metabolized to D-series resolvins and neuroprotectins, while EPA is 
metabolized to E-series resolvins (Serhan et al., 2004). These metabolites have 
anti-inflammatory properties and effects on neural plasticity (Hasturk et al., 
2006; Sun et al., 2007; Xu et al., 2010; Cortina et al., 2013; Erdinest et al., 
2014). Resolvins and neuroprotectins also facilitate cell survival signaling and 
synaptic plasticity (Tassoni et al., 2008; Bazan, 2009; Park et al., 2011; Serhan 
and Petasis, 2011). It is possible that plasticity changes associated with 
increased resolvins and neuroprotectins in the dorsolateral prefrontal cortex 
may mediate the antidepressive and antinociceptive effects of TCAs, 
particularly those with strong noradrenaline reuptake inhibition activity. It is 
postulated that the antinociceptive effect of maprotiline involves the induction 
of iPLA2 activity and subsequent DHA and EPA release. Increased production 
of DHA, EPA and their metabolites may then facilitate activity or plasticity in 
the dorsolateral prefrontal cortex leading to activation of the PAG and 
subsequent descending pain inhibitory pathway. Thus, inhibition of prefrontal 
cortical iPLA2 may prevent activation of the prefrontal cortex and abolish 
PAG stimulation leading to decreased antinociceptive activity of 
antidepressants as shown by maprotiline in our study. 
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Induction of prefrontal cortical iPLA2 was previously revealed to be 
essential for the antidepressive effect of maprotiline, and iPLA2 activity is 
correlated with endogenous release of DHA (Lee et al., 2012). We have also 
shown earlier in the first part of our study that the antinociceptive activity of 
maprotiline also involves prefrontal cortical iPLA2 activity and expression, 
coupled with the production of DHA and EPA. Little, however, is known 
about the possible mechanisms and pathways involved in iPLA2 expression. 
Since maprotiline acts by inhibiting noradrenaline reuptake and increasing the 
level of noradrenaline, it is highly likely that induction of iPLA2 involves 
activation of adrenergic receptors. It is also possible that regulation of iPLA2 
expression induction involves the MAPK/extracellular signal-regulated kinase 
(MAPK/ERK) or cAMP-dependent PKA (cAMP/PKA) signaling pathways 
downstream from the adrenergic receptors. 
The second messenger cAMP/PKA cascade is linked with the 
pathophysiology and treatment of depression (Liu et al., 2012). AC-cAMP-
PKA signaling cascade dysfunction as well as reduced G-protein and cAMP 
levels were shown in patients with depression (Cowburn et al., 1994; Shelton 
et al., 1996; Dowlatshahi et al., 1999). Studies also revealed that chronic 
antidepressant treatment increases AC and GTP expression, induces the level 
and accumulation of forskolin-stimulated cAMP as well as augments PKA 
activity, leading to up-regulation of the cAMP/PKA signaling pathway 
(Nestler et al., 1989; Perez et al., 1989; Ozawa and Rasenick, 1991; Jensen et 
al., 2000). 
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In addition to the cAMP/PKA cascade, there is also evidence 
suggesting a possible role of the MAPK/ERK signaling pathway in the 
maprotiline-induced iPLA2 expression. The MAPK 1 and 3 (ERK1/2) 
activation pathway is one of the most researched alpha-1 adrenergic receptors-
stimulated pathways (Garcia-Sainz et al., 1999; Hague et al., 2002). Inhibition 
of MAPK signaling blocked the behavioral actions of antidepressants, 
resulting in a depressive-like phenotype (Duman et al., 2007). In addition, 
antidepressant efficacy is linked with altered limbic phosphorylated ERK1/2 
in an animal model of chronic depression (Gourley et al., 2008). Researchers 
also showed that the induction of PLA2 protein expression involves the 
MAPK/ERK cascade (Anfuso et al., 2007).  
Besides the cAMP/PKA cascade and MAPK/ERK signaling pathway, 
the sterol regulatory element-binding proteins (SREBPs), in particular 
SREBP-2, may also be implicated in the regulation of iPLA2 induction. 
SREBPs are transcription factors that bind to the SRE DNA sequence 
TCACNCCAC to regulate cellular fatty acid and cholesterol biosynthesis 
(Raeder et al., 2006). There exists two homologous SREBP proteins: SREBP-
1 and SREBP-2 (Raeder et al., 2006). SREBP-1 has two different isoforms, 
SREBP-1a and SREBP-1c, and is mainly involved in regulating genes 
required for fatty acid synthesis while SREBP-2 primarily controls the genes 
involved in cholesterol biosynthesis (Raeder et al., 2006). SREBPs are initially 
generated as inactive precursor proteins located in the membrane of the 
endoplasmic reticulum (ER) (Brown and Goldstein, 1997). Activation of the 
SREBP pathway will induce SREBP translocation to the Golgi apparatus 
where it will be proteolytically cleaved by site-1 protease (S1P) and site-2 
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protease (S2P) to release the cytoplasmic portion of SREBP, which then 
travels to the nucleus to activate transcription of target genes with the SRE 
sequence (Brown and Goldstein, 1997). Antidepressants such as imipramine 
were found to activate the SREBP system, leading to increased expression of 
downstream genes (Raeder et al., 2006). The iPLA2 gene was revealed to 
possess a putative SRE sequence which can bind to SREBP-2 (Seashols et al., 
2004). It was therefore suggested that induction of iPLA2 involves stimulation 
of adrenergic receptors followed by activation of either the cAMP/PKA 
cascade or MAPK/ERK signaling pathway to initiate the SREBP pathway and 
subsequent SREBP-2 binding to the iPLA2 gene. In this part of the study, we 
investigated the role of adrenergic receptors and the possible mechanisms and 
pathways involved in regulation of iPLA2 expression induction. 
Real-time RT-PCR and Western blot analyses were carried out to 
investigate the effect of antidepressant treatment and selective pathway 
inhibitors on SREBP-2 and iPLA2 expression. Electrophoretic mobility shift 
assay (EMSA) was also performed to investigate the effect of maprotiline, 
alpha-1 adrenergic receptor agonist and inhibitor treatment on the binding of 
SREBP-2 to the SRE region of the iPLA2 gene. Lastly, immunocytochemistry 
was carried out to study the effect of maprotiline and inhibitor treatment on 
iPLA2 cellular staining and expression. 
 
2. Materials and methods 
2.1. Cells and treatment 
2.1.1. Cell culture 
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SH-SY5Y neuroblastoma cells obtained from ATCC (Manassas, VA, 
U.S.A.) were used for this part of the study. SH-SY5Y cells are derived from 
the parental SK-N-SH line and they are relatively easy to manipulate and work 
with (Kovalevich and Langford, 2013). Human neuroblastoma cells such as 
LA-N-1 cells and SK-N-SH cells have also been successfully used in previous 
studies that showed novel functions of iPLA2 (Sun et al., 2004). In addition, 
SH-SY5Y cells are shown to express alpha adrenergic receptors and are able 
to synthesize, store and release catecholamines such as noradrenaline 
(Atcheson et al., 1994; Ou et al., 1998; Parsley et al., 1999; Perez, 2005; 
Mathieu et al., 2010; Korecka et al., 2013). The cells were maintained in 
Dulbecco's Modified Eagle Medium (DMEM) supplemented with 1 % 
penicillin-streptomycin solution and 10 % fetal bovine serum (FBS) at 37 °C 
with 5 % CO2 aeration. They were cultured on 100 mm culture plates until 80 
% confluency and used for subsequent treatments.  
 
2.1.2. Treatment with antidepressants 
Treatment with different antidepressants was first carried out to 
investigate their effect on iPLA2 expression. Besides maprotiline and 
amitriptyline, another TCA with strong noradrenaline reuptake inhibiting 
properties, nortriptyline, was used in this part of the study. SH-SY5Y cells 
were separated into 4 groups: 1) Treatment with vehicle, dimethyl sulfoxide 
(DMSO) 2) Treatment with 25 µM maprotiline 3) Treatment with 25 µM 
amitriptyline 4) Treatment with 25 µM nortriptyline. Each group consisted of 
five 100 mm culture plates (n = 5). The in vitro concentrations of 
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antidepressants used are based on other studies (Liao et al., 2010; Hisaoka et 
al., 2011). Incubation was carried out for 24 hours, after which the cells were 
washed in phosphate-buffered saline (PBS) and harvested for real time RT-
PCR analysis. A 24 hour time point was carried out to emulate the chronic 
treatment of antidepressants in the in vivo part of our study. 
 
2.1.3. Treatment with maprotiline and alpha-1 adrenergic receptor blocker 
Treatment with maprotiline and alpha-1 adrenergic receptor blocker 
was carried out to examine their effect on SREBP-2 and iPLA2 expression.  
SH-SY5Y cells were divided into 4 groups: 1) Treatment with vehicle, DMSO 
2) Treatment with 10 µM alpha-1 adrenergic receptor blocker, prazosin 3) 
Treatment with 25 µM maprotiline 4) Treatment with 25 µM maprotiline and 
10 µM prazosin. The concentration of prazosin is based on previous cell 
studies (Segura et al., 2013). Prazosin pre-treatment was carried out for 1 hour, 
followed by maprotiline or vehicle incubation for another 24 hours, after 
which the cells were harvested for real time RT-PCR and Western blot 
analyses. 
 
2.1.4. Treatment with maprotiline and alpha-2 adrenergic receptor blocker  
Treatment with maprotiline and alpha-2 adrenergic receptor blocker 
was performed to study their effect on iPLA2 expression. SH-SY5Y cells were 
divided into 4 groups: 1) Treatment with vehicle, DMSO 2) Treatment with 10 
µM alpha-2 adrenergic receptor blocker, idazoxan 3) Treatment with 25 µM 
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maprotiline 4) Treatment with 10 µM idazoxan and 25 µM maprotiline. The 
concentration of idazoxan is similar to that used in previous studies (Hu et al., 
1996). Idazoxan pre-treatment was carried out for 1 hour, followed by 
maprotiline or vehicle incubation for another 24 hours, after which the cells 
were harvested for real time RT-PCR analysis. 
 
2.1.5. Treatment with maprotiline and non-selective beta adrenergic receptor 
blocker 
Treatment with maprotiline and non-selective beta adrenergic receptor 
blocker was carried out to examine their effect on iPLA2 expression. SH-
SY5Y cells were divided into 4 groups: 1) Treatment with vehicle, DMSO 2) 
Treatment with 10 µM non-selective beta adrenergic receptor blocker, nadolol 
3) Treatment with 25 µM maprotiline 4) Treatment with 10 µM nadolol and 
25 µM maprotiline. The concentration of nadolol used is based on previous 
studies (Cawley et al., 2011). Nadolol pre-treatment was carried out for 1 
hour, followed by maprotiline or vehicle incubation for another 24 hours, after 
which the cells were harvested for real time RT-PCR analysis. 
 
2.1.6. Treatment with maprotiline and serotonin receptor antagonist 
Treatment with maprotiline and serotonin receptor antagonist was 
performed to investigate their effect on iPLA2 expression. SH-SY5Y cells 
were divided into 4 groups: 1) Treatment with vehicle, DMSO 2) Treatment 
with 100 nM selective serotonin receptor antagonist, WAY100635 3) 
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Treatment with 25 µM maprotiline 4) Treatment with 100 nM WAY100635 
and 25 µM maprotiline. The concentration of WAY100635 is similar to that 
used in other cell studies (Jordan et al., 2002). WAY100635 pre-treatment was 
carried out for 1 hour, followed by maprotiline or vehicle incubation for 
another 24 hours, after which the cells were harvested for real time RT-PCR 
analysis. 
 
2.1.7. Treatment with nortriptyline and alpha-1 adrenergic receptor blocker 
Treatment with nortriptyline and alpha-1 adrenergic receptor blocker 
was carried out to study their effect on iPLA2 expression. SH-SY5Y cells were 
divided into 4 groups: 1) Treatment with vehicle, DMSO 2) Treatment with 10 
µM prazosin 3) Treatment with 25 µM nortriptyline 4) Treatment with 10 µM 
prazosin and 25 µM nortriptyline. Prazosin pre-treatment was carried out for 1 
hour, followed by nortriptyline or vehicle incubation for another 24 hours, 
after which the cells were harvested for real time RT-PCR analysis. 
 
2.1.8. Treatment with nortriptyline and serotonin receptor antagonist 
Treatment with nortriptyline and serotonin receptor antagonist was 
performed to determine their effect on iPLA2 expression, SH-SY5Y cells were 
divided into 4 groups: 1) Treatment with vehicle 2) Treatment with 100 nM 
WAY100635 3) Treatment with 25 µM nortriptyline 4) Treatment with 100 
nM WAY100635 and 25 µM nortriptyline. WAY100635 pre-treatment was 
carried out for 1 hour, followed by nortriptyline or vehicle incubation for 
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another 24 hours, after which the cells were harvested for real time RT-PCR 
analysis. 
 
2.1.9. Treatment with maprotiline, cAMP/PKA cascade inhibitors and 
MAPK/ERK signaling pathway inhibitors 
For this part of the study, PKA inhibitors were used to block the 
cAMP/PKA signaling cascade. Treatment with maprotiline, PKA inhibitors 
and MAPK/ERK signaling inhibitors was carried out to investigate their effect 
on SREBP-2 and iPLA2 expression. SH-SY5Y cells were divided into 6 
groups: 1) Treatment with vehicle, DMSO 2) Treatment with 100 nM PKA 
inhibitor, H-89 3) Treatment with 25 µM maprotiline 4) Treatment with 25 
µM maprotiline and 100 nM H-89 5) Treatment with 10 µM of the selective 
ERK inhibitor, FR180204 6)Treatment with 25 µM maprotiline and 10 µM 
FR180204. PKA and MAPK/ERK inhibitor pre-treatment was carried out for 
1 hour, followed by maprotiline or vehicle incubation for another 24 hours, 
after which the cells were harvested for real time RT-PCR analysis. The 
experiments were repeated using 10 nM of another PKA inhibitor, PKI, and 20 
µM of another MAPK/ERK pathway inhibitor, PD98059, to validate their 
effect on SREBP-2 and iPLA2 expression.  The concentrations of PKA 
inhibitors used are based on previous studies (Brigino et al., 1997; Collas et 
al., 1999; Harmon et al., 2005; Queen et al., 2006). The concentrations of 
MAPK/ERK inhibitors used are also similar to those used in previous studies 
(Singh et al., 2009; Volpi et al., 2011; Zeng et al., 2013). 
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2.1.10. Treatment with alpha-1 adrenergic receptor agonist and blocker 
Both maprotiline and nortriptyline have strong noradrenaline reuptake 
inhibition activity which will lead to increasing noradrenaline level and 
subsequent adrenergic receptor activation. Thus, to validate the involvement 
of adrenergic receptors, in particular the alpha-1 adrenergic receptor, in 
SREBP-2 and iPLA2 expression, treatment with alpha-1 adrenergic receptor 
agonist and blocker was carried out. SH-SY5Y cells were divided into 4 
groups: 1) Treatment with vehicle, DMSO 2) Treatment with 10 µM prazosin 
3) Treatment with 50 µM alpha-1 adrenergic receptor agonist, phenylephrine 
4) Treatment with 50 µM phenylephrine and 10 µM prazosin. The 
concentration of phenylephrine used is similar to other cell studies (Endoh and 
Blinks, 1988; Capogrossi et al., 1991). Prazosin pre-treatment was carried out 
for 1 hour, followed by phenylephrine or vehicle incubation for another 24 
hours, after which the cells were harvested for real time RT-PCR analysis. 
 
2.1.11. Treatment with alpha-1 adrenergic receptor agonist, cAMP/PKA 
cascade inhibitors and MAPK/ERK signaling pathway inhibitors 
Treatment with alpha-1 adrenergic receptor agonist, cAMP/PKA and 
MAPK/ERK pathway inhibitors was performed to study their effect on 
SREBP-2 and iPLA2 expression. SH-SY5Y cells were divided into 6 groups: 
1) Treatment with vehicle, DMSO 2) Treatment with 100 nM PKA inhibitor, 
H-89 3) Treatment with 10 µM of the ERK selective inhibitor, FR180204 4) 
Treatment with 50 µM phenylephrine 5) Treatment with 50 µM phenylephrine 
and 10 µM H-89 6) Treatment with 50 µM of phenylephrine and 10 µM 
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FR180204. Inhibitor pre-treatment was carried out for 1 hour, followed by 
phenylephrine or vehicle incubation for another 24 hours, after which the cells 
were harvested for real time RT-PCR analysis. 
 
2.1.12. Treatment with maprotiline and SREBP pathway inhibitors 
Treatment with maprotiline and SREBP pathway inhibitors was carried 
out to examine their effect on iPLA2 expression. The SREBP pathway 
inhibitors used were betulin and the SREBP S1P enzyme inhibitor, PF-
429242. SH-SY5Y cells were divided into 6 groups: 1) Treatment with 
vehicle, DMSO 2) Treatment with 10 µM betulin 3) Treatment with 10 µM 
PF-429242 4) Treatment with 25 µM maprotiline 5) Treatment with 25 µM 
maprotiline and 10 µM betulin 6) Treatment with 25 µM maprotiline and 10 
µM PF-429242. The concentrations of SREBP pathway inhibitors used are 
similar to previous cell studies (Hawkins et al., 2008; Tang et al., 2011). 
Inhibitor pre-treatment was carried out for 1 hour, followed by maprotiline or 
vehicle incubation for another 24 hours, after which the cells were harvested 
for real time RT-PCR analysis. 
 
2.1.13. Treatment with alpha-1 adrenergic receptor agonist and SREBP 
pathway inhibitors 
Treatment with alpha-1 adrenergic receptor agonist and SREBP 
pathway inhibitors was performed to investigate their effects on iPLA2 
expression. SH-SY5Y cells were divided into 6 groups: 1) Treatment with 
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vehicle, DMSO 2) Treatment with 10 µM betulin 3) Treatment with 10 µM 
PF-429242 4) Treatment with 50 µM phenylephrine 5) Treatment with 50 µM 
phenylephrine and 10 µM betulin 6) Treatment with 50 µM phenylephrine and 
10 µM PF-429242. Inhibitor pre-treatment was carried out for 1 hour, 
followed by phenylephrine or vehicle incubation for another 24 hours, after 
which the cells were harvested for real time RT-PCR analysis. 
 
2.2. Real time RT-PCR 
SH-SY5Y RNA samples were reverse transcribed using High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, CA, USA) as 
described previously. Quantitative real-time PCR amplification was then 
carried out in the 7500 Real-time PCR system (Applied Biosystems, CA, 
USA) using TaqMan® Universal PCR Master Mix (Applied Biosystems, CA, 
USA) and Applied Biosystem TaqMan® probes for human SREBP-2, iPLA2 
and beta-actin (Hs01081784_m1, Hs00185926_m1 and #4326315E 
respectively). All reactions were carried out in triplicates and the PCR 
conditions were as described previously.  
 
2.3. Electrophoretic mobility shift assay 
 SREBP-2 is a transcription factor that can bind to the SRE sequence 
present on the iPLA2 gene to induce iPLA2 expression (Seashols et al., 2004). 
Thus, electrophoretic mobility shift assay (EMSA) was performed to 
investigate the effect of maprotiline, alpha-1 adrenergic receptor agonist and 
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blocker treatment on the binding of SREBP-2 to the SRE region of the iPLA2 
gene. Two sets of cell treatment experiments were carried out. For the first set 
of cell treatment, SH-SY5Y cells were divided into 4 groups: 1) Treatment 
with vehicle, DMSO 2) Treatment with 10 µM prazosin 3) Treatment with 50 
µM phenylephrine 4) Treatment with 50 µM phenylephrine and 10 µM 
prazosin. For the second set, SH-SY5Y cells were divided into 4 groups: 1) 
Treatment with DMSO 2) Treatment with 10 µM prazosin 3) Treatment with 
25 µM maprotiline 4) Treatment with 25 µM maprotiline and 10 µM prazosin. 
Prazosin pre-treatment for both sets of cell treatment was carried out for 1 
hour, followed by maprotiline, phenylephrine or vehicle incubation for another 
24 hours, after which protein was extracted from the cells for subsequent 
EMSA analysis. iPLA2 oligonucleotides EMSA probe with the following 
sequences were then synthesized for EMSA analysis: 5′ ACG TCG GTG GTC 
AGG CCA TCA CGT GGC CCG AGG C 3′ and 5′ ACGT TGC CTC GGG 
CCA CGT GAT GGC CTG ACC ACC G 3′. They represent nucleotides -106 
to -77 pf the 5’ flanking region of the iPLA2 gene which contains a SRE 
binding site as shown in a previous study (Seashols et al., 2004). The 
LightShift Chemiluminescent EMSA kit (Thermo Fischer Scientific, IL, USA) 
for gel-shift assays without digoxigenin or radioisotopes was used for EMSA 
analysis. iPLA2 oligonucleotides were first tagged with biotin and 
subsequently annealed. Non-isotopic biotin labeling of the iPLA2 
oligonucleotides EMSA probe was carried out using the DNA 3' End 
Biotinylation Kit (Thermo Fischer Scientific, IL, USA). Binding reactions 
containing the biotin end-labeled iPLA2 oligonucleotides, protein extracts and 
other binding buffer solutions as according to the LightShift 
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Chemiluminescent EMSA kit were then incubated for 20 minutes at room 
temperature. After incubation, the binding reactions were mixed with 5X 
loading buffer, loaded onto a polyacrylamide gel and electrophoresed. The 
binding reactions were then transferred to a nylon membrane, UV cross-
linked, and the binding between biotin-labeled iPLA2 oligonucleotides EMSA 
probe and target SREBP-2 protein was then detected by chemiluminescence. 
Visualized films containing the EMSA blots were scanned and densities of the 
bands measured, using Gel-Pro Analyzer 3.1 program (Media Cybernetics, 
Silver Spring, MD, USA). To check the binding specificity of the iPLA2 
oligonucleotides EMSA probe containing the SRE region of the iPLA2 gene, 
excess unlabeled iPLA2 oligonucleotide was incubated together with the 
labeled iPLA2 oligonucleotide and protein followed by EMSA analysis. 
Binding reactions for control Epstein-Barr Nuclear Antigen (EBNA) system 
were also carried out to ensure that the kit components and overall EMSA 
procedure was working properly. 
 
2.4. Western blot analysis 
Proteins were extracted from SH-SY5Y cells and their concentrations 
were measured as stated previously. Subsequent western blot analysis was 
carried out as described earlier using 30 µg of protein and rabbit polyclonal 
antibody to SREBP-2 (ab30682, Abcam, New Territories, HK; 4 µg/mL).  
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Treatment with maprotiline, alpha-1 adrenergic receptor blocker and 
SREBP pathway inhibitor was carried to examine their effect on iPLA2 
expression and immunolabeling. SH-SY5Y cells were cultured on poly-L-
lysine coated coverslips in 24-well plates and maintained in DMEM 
supplemented with 10 % fetal bovine serum, 1 % penicillin-streptomycin 
solution at 37 °C with 5 % CO2 aeration until reaching 80 % confluency. Cells 
were then separated into 6 treatment groups: 1) Treatment with vehicle, 
DMSO 2) Treatment with 10 µM prazosin 3) Treatment with 25 µM 
maprotiline 4) Treatment with 25 µM maprotiline and 10 µM prazosin 5) 
Treatment with 10 µM betulin 6) Treatment with 25 µM maprotiline and 10 
µM betulin. Prazosin and betulin pre-treatment were carried out for 1 hour 
followed by maprotiline or vehicle incubation for another 24 hours. Cells were 
then washed with PBS and fixed with 2 % paraformaldehyde. After fixing, 
cells were washed with PBS and reacted with 70 % formic acid for 20 minutes 
before undergoing permeabilization by TBS-Triton X for 15 minutes. Cells 
were then blocked in 1 % bovine serum albumin (BSA) in PBS for 1 hour and 
incubated with goat polyclonal anti-iPLA2 (sc-14463, Santa Cruz 
Biotechnology, CA, USA; diluted 1:100 in 1 % BSA) for 1 hour. Cells were 
subsequently washed with PBS and reacted with Alexa Fluor® 488 Donkey 
Anti-Goat IgG (H+L) Antibody (Applied Biosystems, CA, USA; diluted 1:200 
in 1 % BSA) for 1 hour at room temperature. ProLong Gold anti-fade reagent 
with DAPI (Invitrogen, USA) was used as a nuclear counterstaining and 
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mounting agent. Cells were mounted on to glass slides and examined using an 
Olympus FluoView FV1000 confocal microscope. The total cell fluorescence 
corrected for background was then calculated using ImageJ software.  
 
2.6. Statistical analyses 
The mean and standard errors of the values were calculated for each 
experimental group, and possible significant differences between the means 
were detected using one-way ANOVA with Bonferroni post-hoc test. P < 0.05 
was considered significant. 
 
3. Results 
3.1. Real time RT-PCR  
3.1.1. Effect of antidepressant treatment on iPLA2 expression 
 There were significant increases in iPLA2 mRNA expression in SH-
SY5Y cells after treatment with maprotiline (2.36 fold change) and 
nortriptyline (1.42 fold change) for 24 hours. In contrast, no significant 
increase in iPLA2 expression was detected after treatment with amitriptyline 
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Fig. 4.1 Real time RT-PCR results. Effect of antidepressant treatment on 
iPLA2 mRNA expression in SH-SY5Y cells. Analyzed by one-way ANOVA 
with Bonferroni post-hoc test. Asterisks (*) indicate significant differences at 
P < 0.05. N = 5. 
 
3.1.2. Effect of maprotiline and alpha-1 adrenergic receptor blocker on iPLA2 
expression 
There was a significant increase in iPLA2 expression in SH-SY5Y cells 
after treatment with 25 µM maprotiline (2.15 fold change), consistent with the 
increase in iPLA2 expression after maprotiline treatment as shown previously. 
Co-treatment of maprotiline with the alpha-1 adrenergic receptor blocker, 
prazosin, significantly reduced the increase in iPLA2 expression (1.55 fold 
change) (Fig. 4.2). The results suggest the involvement of alpha-1 adrenergic 
receptors in maprotiline-induced iPLA2 expression. 
 
Chapter 4: Regulation of iPLA2 Induction by Adrenergic Receptors, 





Fig. 4.2 Real time RT-PCR results. Effect of maprotiline and alpha-1 
adrenergic receptor blocker, prazosin, on iPLA2 mRNA expression in SH-
SY5Y cells. Analyzed by one-way ANOVA with Bonferroni post-hoc test. 
Asterisks (*) indicate significant differences at P < 0.05. N = 5. 
 
3.1.3. Effect of maprotiline and alpha-2 adrenergic receptor blocker on iPLA2 
expression 
There was a significant 1.8 fold increase in iPLA2 expression after 
treatment with 25 µM maprotiline (Fig. 4.3). Co-treatment with the alpha-2 
adrenergic receptor blocker, idazoxan, did not significantly affect the 
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Fig. 4.3 Real time RT-PCR results. Effect of maprotiline and alpha-2 
adrenergic receptor blocker, idazoxan, treatment on iPLA2 mRNA expression 
in SH-SY5Y cells. Analyzed by one-way ANOVA with Bonferroni post-hoc 
test. Asterisks (*) indicate significant differences at P < 0.05. N = 5. 
 
3.1.4. Effect of maprotiline and non-selective beta adrenergic receptor blocker 
on iPLA2 expression 
There was a significant 1.9 fold increase in iPLA2 expression after 
treatment with 25 µM maprotiline (Fig. 4.4). Co-treatment of maprotiline with 
the non-selective beta adrenergic receptor blocker, nadolol, led to modulation 
of the maprotiline-induced iPLA2 expression although there was still an 
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Fig. 4.4 Real time RT-PCR results. Effect of maprotiline and beta adrenergic 
receptor blocker, nadolol, treatment on iPLA2 mRNA expression in SH-SY5Y 
cells. Analyzed by one-way ANOVA with Bonferroni post-hoc test. Asterisks 
(*) indicate significant differences at P < 0.05. N = 5. 
 
 
3.1.5. Effect of maprotiline with serotonin receptor antagonist on iPLA2 
expression 
There was a significant 2.05 fold increase in iPLA2 expression after 
treatment with 25 µM maprotiline (Fig. 4.5). Co-treatment with the serotonin 
receptor antagonist, WAY100635, did not affect the maprotiline-induced 
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Fig. 4.5 Real time RT-PCR results. Effect of maprotiline and serotonin 
receptor antagonist, WAY100635, treatment on iPLA2 mRNA expression in 
SY-SY5Y cells. Analyzed by one-way ANOVA with Bonferroni post-hoc test. 
Asterisks (*) indicate significant differences at P < 0.05. N = 5. 
 
3.1.6. Effect of nortriptyline with alpha-1 adrenergic receptor blocker on 
iPLA2 expression 
There was a significant increase in iPLA2 expression after treatment 
with 25 µM nortriptyline (1.87 fold change), consistent with the increase in 
iPLA2 expression after nortriptyline treatment as shown previously. Co-
treatment of nortriptyline with prazosin significantly reduced the increase in 
iPLA2 expression (1.44 fold change) (Fig. 4.6). Our results suggest that 
besides being involved in maprotiline-induced iPLA2 expression, the alpha-1 
adrenergic receptors also play a role in nortriptyline-induced iPLA2 
expression. 
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Fig. 4.6 Real time RT-PCR results. Effect of nortriptyline and alpha-1 
adrenergic receptor blocker, prazosin, on iPLA2 mRNA expression in SH-
SY5Y cells. Analyzed by one-way ANOVA with Bonferroni post-hoc test. 
Asterisks (*) indicate significant differences at P < 0.05. N = 5. 
 
3.1.7. Effect of nortriptyline and serotonin receptor antagonist on iPLA2 
expression 
There was a significant 1.91 fold increase in iPLA2 expression after 
treatment with 25 µM nortriptyline (Fig. 4.7). Co-treatment of nortriptyline 
with the serotonin receptor antagonist, WAY100635, did not affect the 
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Fig. 4.7 Real time RT-PCR results. Effect of nortriptyline and serotonin 
receptor antagonist, WAY100635, treatment on iPLA2 mRNA expression in 
SH-SY5Y cells. Analyzed by one-way ANOVA with Bonferroni post-hoc test. 
Asterisks (*) indicate significant differences at P < 0.05. N = 5. 
 
3.1.8. Effect of maprotiline, cAMP/PKA cascade inhibitors and MAPK/ERK 
signaling pathway inhibitors on iPLA2 expression 
There was a significant increase in iPLA2 expression in SH-SY5Y cells 
after treatment with 25 µM maprotiline (1.59 fold change). Co-treatment of 
maprotiline with the PKA inhibitor, H-89, did not affect the maprotiline-
induced increase in iPLA2 expression (Fig. 4.8). However, co-treatment of 
maprotiline with the ERK inhibitor, FR180204, significantly reduced the 
increase in iPLA2 expression (Fig. 4.8). 
In the second set of experiments, there was a significant 2.3 fold 
increase in iPLA2 expression after 25 µM maprotiline treatment. Co-treatment 
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with another PKA inhibitor, PKI, modulated the maprotiline-induced iPLA2 
expression although there was still an increasing trend in iPLA2 expression 
(1.45 fold change) (Fig. 4.9). Co-treatment with another MAPK/ERK pathway 
inhibitor, PD98059, significantly reduced the increase in iPLA2 expression 
(1.56 fold change) (Fig. 4.9). Together, results suggest that there is a stronger 
role for the MAPK/ERK signaling pathway than the cAMP/PKA cascade in 
regulating iPLA2 expression induction. 
 
 
Fig. 4.8 Real time RT-PCR results. Effect of maprotiline together with PKA 
inhibitor, H-89, and ERK inhibitor, FR180204, treatment on iPLA2 mRNA 
expression in SH-SY5Y cells. Analyzed by one-way ANOVA with Bonferroni 
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Fig. 4.9 Real time RT-PCR results. Effect of maprotiline together with PKA 
inhibitor, PKI, and MAPK/ERK pathway inhibitor, PD98059, treatment on 
iPLA2 mRNA expression in SH-SY5Y cells. Analyzed by one-way ANOVA 
with Bonferroni post-hoc test. Asterisks (*) indicate significant differences at 
P < 0.05. N = 5. 
 
3.1.9. Effect of alpha-1 adrenergic receptor agonist and alpha-1 adrenergic 
receptor blocker on iPLA2 expression 
There was a significant increase in iPLA2 expression in SH-SY5Y cells 
after treatment with 50 µM alpha-1 adrenergic receptor agonist, phenylephrine 
(1.67 fold change). Co-treatment of phenylephrine with the alpha-1 adrenergic 
receptor blocker, prazosin, significantly reduced the increase in iPLA2 
expression (1.14 fold) (Fig. 4.10). Results support the involvement of alpha-1 
adrenergic receptors in iPLA2 expression induction. 
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Fig. 4.10 Real time RT-PCR results. Effect of alpha-1 agonist, phenylephrine, 
and alpha-1 adrenergic receptor blocker, prazosin, on iPLA2 mRNA 
expression in SH-SY5Y cells. Analyzed by one-way ANOVA with Bonferroni 
post-hoc test. Asterisks (*) indicate significant differences at P < 0.05. N = 5. 
 
3.1.10. Effect of alpha-1 adrenergic receptor agonist, cAMP/PKA cascade 
inhibitors and MAPK/ERK signaling pathway inhibitors on iPLA2 expression 
There was a significant increase in iPLA2 expression in SH-SY5Y cells 
after treatment with 50µM alpha-1 adrenergic receptor agonist, phenylephrine 
(1.5 fold change). Co-treatment of phenylephrine with the selective ERK 
inhibitor, FR180204, abolished the phenylephrine-induced iPLA2 expression 
(1.04 fold change) while co-treatment of phenylephrine with the PKA 
inhibitor, H-89, also modulated the phenylephrine-induced iPLA2 expression 
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Fig. 4.11 Real time RT-PCR results. Effect of alpha-1 agonist, phenylephrine, 
and PKA inhibitor, H-89, and ERK inhibitor, FR180204, treatment on iPLA2 
mRNA expression in SH-SY5Y cells. Analyzed by one-way ANOVA with 
Bonferroni post-hoc test. Asterisks (*) indicate significant differences at P < 
0.05. N = 5. 
 
3.1.11. Effect of maprotiline and alpha-1 adrenergic receptor blocker on 
SREBP-2 expression 
There was a significant increase in SREBP-2 expression in SH-SY5Y 
cells after treatment with 25 µM maprotiline (4.07 fold change). Co-treatment 
of maprotiline with the alpha-1 adrenergic receptor blocker, prazosin, 
significantly reduced the increase in SREBP-2 expression (Fig. 4.12). Results 
suggest that alpha-1 adrenergic receptors also play a role in maprotiline-
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Fig. 4.12 Real time RT-PCR results. Effect of maprotiline and alpha-1 
adrenergic receptor blocker, prazosin, on SREBP-2 mRNA expression in SH-
SY5Y cells. Analyzed by one-way ANOVA with Bonferroni post-hoc test. 
Asterisks (*) indicate significant differences at P < 0.05. N = 5. 
 
3.1.12. Effect of maprotiline, cAMP/PKA cascade inhibitors and MAPK/ERK 
signaling pathway inhibitors on SREBP-2 expression 
There was a significant increase in SREBP-2 expression in SH-SY5Y 
cells after treatment with 25 µM maprotiline (3.06 fold change). Co-treatment 
of maprotiline with the PKA inhibitor, H-89, did not affect the increase in 
SREBP-2 expression (2.99 fold change) (Fig. 4.13).  However, co-treatment of 
maprotiline with the selective ERK inhibitor, FR180204, significantly reduced 
the increase in SREBP-2 expression (Fig. 4.13).  
In a second set of experiments, co-treatment with another PKA 
inhibitor, PKI, modulated the increase in SREBP-2 expression (Fig. 4.14). Co-
treatment with another MAPK/ERK pathway inhibitor, PD98059, also 
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significantly reduced the maprotiline-induced SREBP-2 expression (2.65 fold 
change) (Fig. 4.14). Together, results suggest a stronger involvement of the 
MAPK/ERK signaling pathway as compared to the cAMP/PKA cascade in 
maprotiline-induced SREBP-2 expression. 
 
 
Fig. 4.13 Real time RT-PCR results. Effect of maprotiline together with PKA 
inhibitor, H-89, and ERK inhibitor, FR180204, treatment on SREBP-2 mRNA 
expression in SH-SY5Y cells. Analyzed by one-way ANOVA with Bonferroni 
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Fig. 4.14 Real time RT-PCR results. Effect of maprotiline together with PKA 
inhibitor, PKI, and MAPK/ERK pathway inhibitor, PD98059, treatment on 
SREBP-2 mRNA expression in SH-SY5Y cells. Analyzed by one-way 
ANOVA with Bonferroni post-hoc test. Asterisks (*) indicate significant 
differences at P < 0.05. N = 5. 
 
3.1.13. Effect of alpha-1 adrenergic receptor agonist and blocker on SREBP-2 
expression 
There was a significant increase in SREBP-2 expression in SH-SY5Y 
cells after treatment with 50 µM alpha-1 agonist, phenylephrine (1.67 fold 
change). Co-treatment of phenylephrine with the alpha-1 adrenergic receptor 
blocker, prazosin, significantly abolished the increase in SREBP-2 expression 
(0.99 fold change) (Fig. 4.15).  
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Fig. 4.15 Real time RT-PCR results. Effect of alpha-1 agonist, phenylephrine, 
and alpha-1 adrenergic receptor blocker, prazosin, on SREBP-2 mRNA 
expression in SH-SY5Y cells. Analyzed by one-way ANOVA with Bonferroni 
post-hoc test. Asterisks (*) indicate significant differences at P < 0.05. N = 5. 
 
3.1.14. Effect of alpha-1 adrenergic receptor agonist, cAMP/PKA cascade 
inhibitors and MAPK/ERK signaling pathway inhibitors on SREBP-2 
expression 
There was a significant increase in SREBP-2 expression in SH-SY5Y 
cells after treatment with 50 µM agonist, phenylephrine (1.43 fold change). 
Co-treatment of phenylephrine with the ERK inhibitor, FR180204, abolished 
the increase in SREBP-2 expression (0.97 fold change), whereas co-treatment 
with the PKA inhibitor, H-89, had no effect on SREBP-2 expression (2.05 fold 
change) (Fig. 4.16). Results further support the role of the MAPK/ERK 
signaling pathway in SREBP-2 expression. 
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Fig. 4.16 Real time RT-PCR results. Effect of alpha-1 agonist, phenylephrine, 
and PKA inhibitor, H-89, and ERK inhibitor, FR180204, treatment on 
SREBP-2 mRNA expression in SH-SY5Y cells. Analyzed by one-way 
ANOVA with Bonferroni post-hoc test. Asterisks (*) indicate significant 
differences at P < 0.05. N = 5. 
 
3.1.15. Effect of maprotiline and SREBP pathway inhibitors on iPLA2 
expression 
There was a significant increase in iPLA2 expression in SH-SY5Y cells 
after treatment with 25 µM maprotiline (2.25 fold change). Co-treatment of 
maprotiline with the SREBP pathway inhibitors, betulin and PF-429242, 
significantly abolished the increase in iPLA2 expression (0.97 fold change and 
1.25 fold change respectively) (Fig. 4.17). Results highlight the importance of 
the SREBP pathway in regulating iPLA2 expression induction. 
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Fig. 4.17 Real time RT-PCR results. Effect of maprotiline and SREBP 
pathway inhibitors, betulin and PF-429242, treatment on iPLA2 mRNA 
expression in SH-SY5Y cells. Analyzed by one-way ANOVA with Bonferroni 
post-hoc test. Asterisks (*) indicate significant differences at P < 0.05. N = 5. 
 
3.1.16. Treatment with alpha-1 adrenergic receptor agonist and SREBP 
pathway inhibitors on iPLA2 expression 
There was a significant increase in iPLA2 expression in SH-SY5Y cells 
after treatment with 50 µM alpha-1 receptor agonist, phenylephrine (1.41 fold 
change). Co-treatment of phenylephrine with the SREBP pathway inhibitor, 
betulin significantly reduced the phenylephrine-induced iPLA2 expression 
(1.05 fold change). Co-treatment of phenylephrine with PF-429242 also 
abolished the phenylephrine-induced iPLA2 expression (0.91 fold change) 
(Fig. 4.18). Results further support that the SREBP pathway plays a role in 
iPLA2 expression induction. 
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Fig. 4.18 Real time RT-PCR results. Effect of alpha-1 adrenergic receptor 
agonist, phenylephrine, and SREBP pathway inhibitors, betulin and PF-
429242, treatment on iPLA2 mRNA expression in SH-SY5Y cells. Analyzed 
by one-way ANOVA with Bonferroni post-hoc test. Asterisks (*) indicate 
significant differences at P < 0.05. N = 5. 
 
3.2. Electrophoretic mobility shift assay 
3.2.1. Effectiveness and binding specificity of iPLA2 oligonucleotides EMSA 
probe to SREBP-2 
To check the effectiveness and binding specificity of the iPLA2 
oligonucleotides EMSA probe containing the SRE region of the iPLA2 gene, 
labeled iPLA2 oligonucleotides EMSA probe and protein were incubated 
together with and without excess unlabeled iPLA2 oligonucleotides followed 
by EMSA analysis. There was a shift present after labeled iPLA2 
oligonucleotides EMSA probe and protein incubation indicating binding of 
SREBP-2 to the SRE region of the iPLA2 oligonucleotides, consistent with the 
EMSA results in a previous study which showed binding of SREBP-2 to the 
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EMSA probe (Seashols et al., 2004). Competition with excess unlabeled 
iPLA2 oligonucleotide blocked this shift indicating binding specificity of 
iPLA2 oligonucleotides EMSA probe to SREBP-2 (Fig. 4.19). 
 
 
Fig. 4.19 EMSA blot showing the effectiveness and binding specificity of 
iPLA2 oligonucleotides EMSA probe to SREBP-2. In Lane 1, there is no 
protein for the iPLA2 EMSA probe to bind, thus no shift was observed. In 
Lane 2, there is protein present to effect the binding and shift of SREBP-2 and 
labeled iPLA2 EMSA probe. A shift was thus detected in Lane 2 as compared 
to Lane 1. In Lane 3, the signal shift observed in Lane 2 was blocked by 
competition with excess unlabeled iPLA2 EMSA probe indicating that the shift 
in Lane 2 is due to specific binding interactions between the target SREBP-2 
protein and labeled iPLA2 EMSA probe. 
 
3.2.2. Effect of maprotiline and alpha-1 adrenergic receptor blocker treatment 
on the binding of SREBP-2 to the SRE region of the iPLA2 gene 
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EMSA blot showed binding between SREBP-2 and labeled iPLA2 
oligonucleotides EMSA probe, similar to the EMSA blot presented earlier and 
consistent with a previous study (Seashols et al., 2004). Densitometric analysis 
found that there was a significant increase in SREBP-2 binding to the iPLA2 
oligonucleotides EMSA probe containing the SRE region of the iPLA2 gene 
after maprotiline treatment (Fig. 4.20). Pre-treatment with the alpha-1 
adrenergic receptor blocker, prazosin, significantly abolished this increase in 
SREBP-2 binding. Control EBNA system showed that the overall EMSA 
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Fig. 4.20 EMSA blot densitometric analysis results. (A) EMSA blot and (B) 
densitometric analysis on the effects of maprotiline treatment and alpha-1 
adrenergic receptor blocker, prazosin, on SREBP-2 binding to the SRE region 
of iPLA2 gene. Analyzed by one-way ANOVA with Bonferroni post-hoc test. 
Asterisks (*) indicate significant differences at P < 0.05. 
 
3.2.3. Effect of alpha-1 adrenergic receptor agonist and alpha-1 adrenergic 
receptor blocker treatment on the binding of SREBP-2 to the SRE region of 
the iPLA2 gene 
EMSA blot showed binding between SREBP-2 and labeled iPLA2 
oligonucleotides EMSA probe, similar to the EMSA blot presented earlier and 
consistent with a previous study (Seashols et al., 2004). Densitometric analysis 
revealed that there was a significant increase in SREBP-2 binding to the iPLA2 
oligonucleotides containing the SRE region of the iPLA2 gene after treatment 
with alpha-1 adrenergic receptor agonist, phenylephrine (Fig. 4.21). Pre-
treatment with the alpha-1 receptor blocker, prazosin abolished the increase in 
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SREBP2 binding. Control EBNA system showed that the overall EMSA 





Fig. 4.21 EMSA blot densitometric analysis results. (A) EMSA blot and (B) 
densitometric analysis on the effect of alpha-1 adrenergic receptor agonist, 
phenylephrine, and alpha-1 adrenergic receptor blocker, prazosin, treatment on 
SREBP-2 binding to the SRE region of iPLA2 gene. Analyzed by one-way 
ANOVA with Bonferroni post-hoc test. Asterisks (*) indicate significant 
differences at P < 0.05. 
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3.3. Western blot analysis 
Western blot analysis showed the presence of a band at approximately 
55 kDa which corresponds to the band size of activated SREBP-2 protein. 
Densitometric analysis of the protein blots showed a significant 2.17 fold 
increase in SREBP-2 protein expression in the SH-SY5Y cells after 
maprotiline treatment, compared to vehicle controls. This increase in SREBP-
2 protein expression was significantly abolished after treatment with the alpha-
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Fig. 4.22 Western blot densitometric analysis results. (A) Western blot and (B) 
densitometric analysis on the effect of maprotiline and alpha-1 adrenergic 
receptor blocker, prazosin, treatment on SREBP-2 expression in SH-SY5Y 
cells. Analyzed by one-way ANOVA with Bonferroni post-hoc test. Asterisks 
(*) indicate significant differences at P < 0.05. 
 
3.4. Immunocytochemistry 
iPLA2 immunofluorescence labeling showed localization of iPLA2 
protein in the cytoplasm (Fig. 4.23). A significant increase in fluorescence 
intensity was observed after maprotiline treatment, compared to vehicle 
control (Fig. 4.24). Blockade of alpha-1 adrenergic receptors by prazosin, or 
SREBP pathway by betulin, significantly abolished the maprotiline-induced 
increase in immunofluorescence.  
 




Fig. 4.23 Immunocytochemistry photos of iPLA2 expression in SH-SY5Y cells after maprotiline, alpha-1 adrenergic receptor blocker, prazosin, 
and SREBP pathway inhibitor, betulin, treatment.
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Fig. 4.24 Fluorescence intensity of iPLA2 expression in SH-SY5Y cells after 
maprotiline, alpha-1 adrenergic receptor blocker, prazosin, and SREBP 
pathway inhibitor, betulin treatment. Analyzed by one-way ANOVA with 




This part of the study was carried out to investigate the role of 
adrenergic receptors and the possible mechanisms and pathways involved in 
regulation of iPLA2 expression induction. Our previous study showed that 
maprotiline caused a significant increase in iPLA2 expression in the mouse 
prefrontal cortex (Lee et al., 2012), and this was supported by the first part of 
this study. Similarly, real-time RT-PCR results showed that iPLA2 expression 
in SH-SY5Y cells was significantly increased after maprotiline treatment. 
There was also a significant increase in iPLA2 expression after nortriptyline 
but not amitriptyline treatment. Nortriptyline is a TCA with serotonin and 
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noradrenaline reuptake inhibition activity but with stronger selectivity for the 
inhibition of noradrenaline reuptake (Baldessarini, 2006; Rang et al., 2007). 
Thus, it is possible that the increase in iPLA2 expression after maprotiline and 
nortriptyline treatment primarily involves inhibition of noradrenaline reuptake, 
leading to higher noradrenaline level and subsequent activation of the 
adrenergic receptors.  
The involvement of adrenergic receptors in the antidepressant-induced 
iPLA2 expression was further investigated, using adrenergic and serotonin 
receptor blockers. Treatment with the alpha-1 adrenergic receptor blocker, 
prazosin, significantly abrogated the maprotiline-induced increase in iPLA2 
expression. In addition, prazosin also significantly abolished the nortriptyline-
induced iPLA2 expression, suggesting that alpha-1 adrenergic receptors are 
essential for iPLA2 expression induction. Alpha-1 adrenergic receptors are 
mainly located on the postsynaptic membrane (Starke et al., 1989; Rang et al., 
2007). Neurotransmission facilitation by the alpha-1 adrenergic receptor has 
been found to be involved in the effect of antidepressant therapy (Vetulani, 
1984; Vetulani et al., 1984). Studies also revealed that chronic antidepressant 
treatment caused an eventual up-regulation of alpha-1 adrenergic receptors 
coupled with a down-regulation of alpha-2 and beta adrenergic receptors in the 
rat cerebral cortex (Vetulani, 1984; Vetulani et al., 1984). The importance of 
alpha-1 adrenergic receptors in depression and antidepressant therapy was 
further highlighted by a study showing that a reduction in alpha-1 
noradrenergic transmission resulted in depressive behavior (Stone and 
Quartermain, 1999). In comparison, treatment with idazoxan, a selective 
alpha-2 adrenergic receptor blocker, did not inhibit the increase in iPLA2 
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expression induced by maprotiline treatment in SH-SY5Y cells. We also 
investigated a potential role of serotonin receptors in the antidepressant-
induced iPLA2 expression using a serotonin receptor blocker, WAY100635 
(Fletcher et al., 1996). Treatment with WAY100635 did not significantly 
affect the increase in iPLA2 expression after maprotiline or nortriptyline 
treatment. Together, our results suggest that the alpha-1 adrenergic receptor 
has an important role in regulation of iPLA2 expression induction. This was 
further supported by our findings that treatment with the alpha-1 adrenergic 
receptor agonist, phenylephrine, also caused a significant albeit lower increase 
in iPLA2 expression as compared to antidepressant treatment. In addition, this 
increase in iPLA2 expression after phenylephrine treatment was significantly 
abolished by co-treatment with prazosin, further supporting the role of alpha-1 
adrenergic receptors in iPLA2 expression. 
Regulation of iPLA2 expression may also involve the MAPK/ERK or 
cAMP/PKA signaling pathways downstream from the adrenergic receptors. 
We then studied the potential roles of these signaling pathways in mediating 
iPLA2 expression induction using specific signaling pathway inhibitors. 
Treatment with MAPK/ERK pathway inhibitors significantly abolished the 
maprotiline-induced expression of iPLA2, indicating involvement of the 
MAPK/ERK signaling pathway in iPLA2 expression induction. As stated 
earlier, one of the most studied alpha-1 adrenergic receptors-stimulated 
pathways is the ERK1/2 activation signaling pathway (Garcia-Sainz et al., 
1999; Hague et al., 2002). Alpha-1 adrenergic receptors are G protein-coupled 
receptors and are activated by adrenaline and noradrenaline (Garcia-Sainz et 
al., 1999). Besides ERK1/2, alpha-1 adrenergic receptors are involved in 
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activation of PKC which was also shown to mediate iPLA2 expression and 
activity (Garcia-Sainz et al., 1999; Hu et al., 1999; Rohde et al., 2000; Steer et 
al., 2002; Meyer et al., 2005). Moreover, induction of PLA2 protein expression 
in endothelial cell-pericyte co-cultures was found to involve activation of PKC 
and the MAPK/ERK cascade, further supporting the involvement of the 
MAPK/ERK signaling pathway in mediating iPLA2 expression induction 
(Anfuso et al., 2007). Besides the MAPK/ERK signaling pathway, the cAMP-
dependent cascade which involves PKA activation could potentially have a 
role in the up-regulation of iPLA2 expression. However, treatment with PKA 
inhibitors failed to significantly abolish the increase in iPLA2 expression, 
suggesting that the cAMP/PKA pathway does not play a key role in iPLA2 
expression. Together, our results support a role of MAPK/ERK signaling 
pathway rather than the cAMP/PKA cascade in iPLA2 expression induction. 
SREBP-2 is a transcription factor and was previously shown to be 
involved in iPLA2 expression (Seashols et al., 2004). The effect of 
antidepressant and alpha-1 adrenergic receptor agonist treatment on SREBP-2 
expression was thus further elucidated. Treatment with maprotiline 
significantly increased SREBP-2 mRNA expression and this increase was 
abrogated by blockade of the alpha-1 adrenergic receptors with prazosin. 
Similarly, phenylephrine significantly increased SREBP-2 mRNA expression 
and this increase was abolished when the alpha-1 adrenergic receptors were 
blocked with prazosin, highlighting the involvement of alpha-1 adrenergic 
receptors in both iPLA2 and SREBP-2 expression. MAPK/ERK pathway 
inhibitors also significantly abolished the increase SREBP-2 expression, 
indicating the involvement of the MAPK/ERK signaling cascade in SREBP-2 
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as well as iPLA2 expression. This was supported by a previous study that 
showed an association between SREBP-2 and the MAPK/ERK signaling 
cascade (Kotzka et al., 2000). In that study, a direct link was found between 
MAPK activity and SREBPs as ERK1 and ERK2 were shown to 
phosphorylate GST-fusion SREBP-2 protein in vitro, suggesting that SREBP-
2 is a direct substrate of ERK1 and ERK2. SREBP pathway inhibitors were 
then used to study the effect of SREBP inhibition on iPLA2 expression 
induction. Our results showed that treatment with SREBP pathway inhibitors, 
betulin and PF-429242, significantly abolished the maprotiline-induced 
increase in iPLA2 expression. SREBP pathway inhibitors also abrogated the 
phenylephrine-induced iPLA2 expression. Betulin inhibits the maturation of 
SREBP while PF-429242 selectively inhibits S1P, an enzyme involved in the 
release of mature activated SREBP (Hawkins et al., 2008; Tang et al., 2011). 
Based on our results, it was then suggested that SREBP-2 is essential for 
iPLA2 expression induction and is similarly regulated by alpha-1 adrenergic 
receptors and the MAPK/ERK signaling pathway. 
A previous study showed a link between SREBP-2 and the iPLA2 
promoter, which contains the SRE sequence. A mutant cell line that 
constitutively produces mature SREBP proteins showed increased iPLA2 
expression and activity (Seashols et al., 2004). EMSA analysis showed that 
mature SREBP-2 forms a complex with a 30-mer EMSA probe corresponding 
to the SRE sequence in the iPLA2 promoter region (Seashols et al., 2004). 
Based on these seminal findings, EMSA analysis was carried out in our study 
using a non-radioactive iPLA2 EMSA probe with the same oligonucleotide 
sequences as used in the aforementioned study (Seashols et al., 2004). Our 
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results confirmed that SREBP-2 indeed binds to the SRE region of the iPLA2 
promoter and treatment with both maprotiline and phenylephrine significantly 
increased this binding. The increase in binding was abolished by co-treatment 
with prazosin, consistent with a role of alpha-1 adrenergic receptors in causing 
an increase in SREBP-2 and iPLA2 expression. Results from our western blot 
analysis also confirmed that maprotiline treatment increased SREBP-2 
expression and this increase was significantly blocked by co-treatment with 
prazosin. Immunocytochemical staining showed an increase in iPLA2 
immunostaining after maprotiline treatment, and this increase was 
significantly abolished by blockade of alpha-1 adrenergic receptors with 
prazosin and inhibition of the SREBP pathway with betulin. These results 
corroborate the RT-PCR and EMSA findings and further emphasize the role of 
alpha-1 adrenergic receptors and SREBP pathway in iPLA2 expression. 
Overall, results from the present study indicate that stimulation of 
alpha-1 adrenergic receptors causes increased iPLA2 expression via the 
MAPK/ERK signaling pathway and SREBP-2 protein. It is important to note 
however, that this study was carried out under in vitro conditions and further 
study is needed to validate these findings in an in vivo setting. Nonetheless, 
our findings may potentially provide a basis for further research on the 
regulation of iPLA2 expression and possible crosstalk between sterol and 
glycerophospholipid mediators that may play a role in physiological or 
pathophysiological processes in the brain and other organs. 
 









Chapter 5: Effect of Antidepressant Treatment on 15-
LOX Expression  




We have established earlier that antidepressant treatment, especially 
those with strong noradrenaline reuptake inhibition activity, induced an up-
regulation in iPLA2 expression. Increasing iPLA2 expression and activity will 
lead to enhanced production of DHA which can then be metabolized by 15-
LOX to produce resolvins and neuroprotectins (Farooqui, 2011). 15-LOX is a 
member of the non-heme LOX family of enzymes which have dioxygenase 
activity and a molecular weight of around 75-78 kDa (Radmark and 
Samuelsson, 2009). They are essential for the dioxygenation or the insertion of 
molecular oxygen into PUFAs in lipids (Radmark and Samuelsson, 2009). The 
molecular structure of LOX consists of a single polypeptide chain which folds 
into two domains (Brash, 2001). Besides 15-LOX, there are three other types 
of LOX: 5-LOX, 8-LOX and 12-LOX. LOX enzymes are categorized 
according to the position of oxygen insertion where the dioxygenation takes 
place, either at carbon 5, 8, 12, or 15 of the aliphatic chain (Phillis et al., 
2006). Out of the four different LOX enzymes, only three are present in the 
brain: 5-LOX, 12-LOX and 15-LOX. 
15-LOX is also known as arachidonate 15-LOX and is encoded by the 
ALOX15 gene. As stated earlier, 15-LOX catalyzes the metabolism of DHA 
into docosanoids consisting of resolvins and neuroprotectins. DHA is a 
precursor for the production of D-series resolvins and DHA is first converted 
into 17S-hydroperoxy-DHA (17S-H(p)DHA) with the involvement of 15-
LOX (Serhan and Chiang, 2008; Farooqui, 2011; Ji et al., 2011). 17S-
H(p)DHA is then catalyzed into several different bioactive compounds such as 
RvD1 (Fig. 5.1). 15-LOX is also involved in the conversion of NPD1 from 
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DHA in the brain via epoxide intermediates with the epoxy group located at 
the 16(17) position (Hong et al., 2003; Farooqui, 2011). Resolvins are 
suggested to act via specific receptors called resolvin D receptors which can 
be found in neural as well as non-neural cells and they are essential in 
stimulating strong immunoregulatory and anti-inflammatory activities (Serhan 
et al., 2008a; Serhan et al., 2008b). DHA and its metabolites have been shown 
to have a significant role on synaptic functions and resolvins were suggested 
to normalize the spinal synaptic plasticity linked with pain hypersensitivity 
(Xu et al., 2010; Farooqui, 2011). RvD1 was also shown to have pro-resolving 
and anti-inflammatory properties in ocular surface inflammation and cigarette 
smoke-induced lung inflammation (Hsiao et al., 2013; Erdinest et al., 2014). 
Furthermore, resolvins and neuroprotectins can modulate the effects of 
proinflammatory eicosanoids derived from AA (Hong et al., 2003). Any 
changes in 15-LOX expression will then impact the generation of resolvins 
and neuroprotectins, affecting their overall anti-inflammatory and 
neuroprotective effects. 
In view that iPLA2 expression was increased after maprotiline and 
nortriptyline treatment, leading to increased production of DHA which is the 
precursor for resolvins and neuroprotectins, it is possible that 15-LOX may 
also be affected by antidepressant treatment and regulated in a similar way as 
iPLA2. We then postulate that besides inducing iPLA2 expression, 
antidepressants especially those with strong noradrenaline reuptake inhibition 
activity will similarly stimulate the expression of 15-LOX enzyme. In this part 
of the study, we studied the effect of antidepressant treatment on 15-LOX 
expression. 
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Real-time RT-PCR and Western blot analyses were carried out to 
investigate the effect of antidepressant treatment on 15-LOX expression in 
SH-SY5Y cells. Co-treatment with alpha-1 adrenergic receptor blocker, 
prazosin, was also performed to study the involvement of alpha-1 adrenergic 
receptors in 15-LOX expression.  
 
 
Fig. 5.1 The metabolic steps involved in generation of neuroprotectin D1 
(NPD1) and resolvin D1 (RvD1) from DHA. Adapted from (Rius et al., 2012) 
 
2. Materials and method 
2.1. Cell culture 
 For this part of the study, SH-SY5Y cells were similarly obtained from 
ATCC (Manassas, VA, U.S.A.) and used for cell culture experiments. The 
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cells were cultured until reaching approximately 80% confluency and 
maintained in DMEM supplemented with 10 % fetal bovine serum, 1 % 
penicillin-streptomycin solution at 37 °C with 5 % CO2 aeration. Cells were 
then separated into treatment groups where each group consisted of five 100 
mm culture plates for subsequent analyses (n = 5). 
 
2.1.1. Treatment with antidepressants 
Treatment with different antidepressants was first carried out to 
investigate their effect on 15-LOX expression. SH-SY5Y cells were divided 
into 4 groups: 1) Treatment with vehicle, DMSO 2) Treatment with 25 µM 
maprotiline 3) Treatment with 25 µM amitriptyline 4) Treatment with 25 µM 
nortriptyline. Incubation was carried out for 24 hours, after which the cells 
were washed in PBS and harvested for real-time RT-PCR analysis. 
 
2.1.2. Treatment with maprotiline and alpha-1 adrenergic receptor blocker 
Treatment with maprotiline and alpha-1 adrenergic receptor blocker 
was performed to determine their effect on 15-LOX expression. SH-SY5Y 
cells were divided into 4 groups: 1) Treatment with vehicle, DMSO 2) 
Treatment with 10 µM prazosin 3) Treatment with 25 µM maprotiline 4) 
Treatment with 25 µM maprotiline and 10 µM prazosin. Prazosin pre-
treatment was carried out for 1 hour followed by maprotiline or vehicle 
incubation for another 24 hours, after which the cells were harvested for real-
time RT-PCR and Western blot analyses. 




2.1.3. Treatment with nortriptyline and alpha-1 adrenergic receptor blocker 
Treatment with nortriptyline and alpha-1 adrenergic receptor blocker 
was carried out to study their effect on 15-LOX expression. SH-SY5Y cells 
were divided into 4 groups: 1) Treatment with DMSO 2) Treatment with 10 
µM prazosin 3) Treatment with 25 µM nortriptyline 4) Treatment with 25 µM 
nortriptyline and 10 µM prazosin. Prazosin pre-treatment was carried out for 1 
hour followed by nortriptyline or vehicle incubation for another 24 hours, after 
which the cells were harvested for real-time RT-PCR analysis. 
 
2.2. Real-time RT-PCR 
SH-SY5Y RNA samples were reverse transcribed using High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, CA, USA) as 
described previously. Quantitative real-time PCR amplification was then 
carried out in the 7500 Real-time PCR system (Applied Biosystems, CA, 
USA) using TaqMan® Universal PCR Master Mix (Applied Biosystems, CA, 
USA) and Applied Biosystem TaqMan® probes for human 15-LOX 
(ALOX15) and beta-actin (Hs00609608_m1 and #4326315E respectively). All 
reactions were carried out in triplicates and the PCR conditions were as 
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2.3. Western blot analysis 
Proteins were extracted from SH-SY5Y cells and their concentrations 
were measured as stated previously. Subsequent western blot analysis was 
carried out as described earlier using 30 µg of protein and mouse monoclonal 
antibody to 15-LOX (ab119774, Abcam, New Territories, HK; diluted 1:500). 
 
2.4. Statistical analysis 
The mean and standard errors of the values were calculated for each 
experimental group, and possible significant differences between the means 
were examined using one-way ANOVA with Bonferroni post-hoc test. P < 
0.05 was considered significant. 
 
3. Results 
3.1. Real time RT-PCR 
3.1.1. Antidepressant treatment 
 Real-time RT-PCR showed a significant increase in 15-LOX mRNA 
expression in SH-SY5Y cells after maprotiline (2.09 fold change) and 
nortriptyline (1.96 fold change) treatment for 24 hours. However, there was no 
significant increase in 15-LOX expression after amitriptyline treatment (0.96 
fold change) (Fig. 5.2).  
 




Fig. 5.2 Real time RT-PCR results. Effect of antidepressant treatment on 15-
LOX mRNA expression in SH-SY5Y cells. Analyzed by one-way ANOVA 
with Bonferroni post-hoc test. Asterisks (*) indicate significant differences at 
P < 0.05. N = 5. 
 
3.1.2. Treatment with maprotiline and alpha-1 adrenergic receptor blocker 
Real-time RT-PCR showed a significant 1.7 fold increase in 15-LOX 
mRNA expression after maprotiline treatment (Fig. 5.3). Treatment with 
alpha-1 adrenergic receptor blocker, prazosin, significantly abolished this 
increase (0.96 fold change). Results suggest the involvement of alpha-1 
adrenergic receptors in 15-LOX expression induction. 
 




Fig. 5.3 Real time RT-PCR results. Effect of maprotiline and alpha-1 
adrenergic receptor blocker, prazosin, on 15-LOX mRNA expression in SH-
SY5Y cells. Analyzed by one-way ANOVA with Bonferroni post-hoc test. 
Asterisks (*) indicate significant differences at P < 0.05. N = 5. 
 
3.1.3. Treatment with nortriptyline and alpha-1 adrenergic receptor blocker 
Real-time RT-PCR showed a significant 1.79 fold increase in 15-LOX 
mRNA expression after nortriptyline treatment (Fig. 5.4). Treatment with 
alpha-1 adrenergic receptor blocker significantly abolished this increase (1.19 
fold change). Results showed that besides being involved in maprotiline-
induced 15-LOX expression, alpha-1 adrenergic receptors are also essential 
for the nortriptyline-induced expression of 15-LOX.  
 




Fig. 5.4 Real time RT-PCR results. Effect of nortriptyline and alpha-1 
adrenergic receptor blocker, prazosin, on 15-LOX mRNA expression in SH-
SY5Y cells. Analyzed by one-way ANOVA with Bonferroni post-hoc test. 
Asterisks (*) indicate significant differences at P < 0.05. N = 5. 
 
3.2. Western blot analysis 
Western blot analysis showed the presence of a band at approximately 
75 kDa which corresponds to the band size of 15-LOX protein. Densitometric 
analysis of the protein blots showed a significant 2.10 fold change increase in 
15-LOX protein expression in the SH-SY5Y cells after maprotiline treatment, 
compared to vehicle controls (Fig. 5.5). The increase in 15-LOX expression 
was significantly abolished after treatment with the alpha-1 adrenergic 
receptor blocker, prazosin (0.47 fold change). 
 





Fig. 5.5 Western blot densitometric analysis results. (A) Western blot and (B) 
densitometric analysis on the effect of maprotiline and alpha-1 adrenergic 
receptor blocker, prazosin, treatment on 15-LOX expression in SH-SY5Y 
cells. Analyzed by one-way ANOVA with Bonferroni post-hoc test. Asterisks 
(*) indicate significant differences at P < 0.05. 
 
4. Discussion 
This part of the study was carried out to investigate the effect of 
antidepressant treatment on 15-LOX expression in SH-SY5Y cells. 
Administration of maprotiline significantly increased 15-LOX mRNA 
expression. Nortriptyline treatment showed a similar significant increase in 
15-LOX expression. Treatment with amitriptyline, however, did not affect 15-
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LOX expression. The effect of antidepressant treatment on 15-LOX 
expression was found to have a similar trend as the antidepressant action on 
iPLA2 expression where maprotiline and nortriptyline increased both iPLA2 
and 15-LOX expression but amitriptyline did not have any effect. Thus, it is 
possible that 15-LOX and iPLA2 both share common signaling pathways or 
mechanisms in regulating their expression induction. 
As stated previously, maprotiline and nortriptyline both have strong 
effects on the noradrenaline transporter and weaker activity on the serotonin 
transporter as compared to amitriptyline (Frazer, 1997a). Thus, like iPLA2, 15-
LOX expression was also suggested to involve activation of the alpha-1 
adrenergic receptors by maprotiline and nortriptyline treatment. This was 
further investigated using the alpha-1 adrenergic receptor blocker, prazosin. 
Blockade of the alpha-1 adrenergic receptor by prazosin significantly 
abolished maprotiline and nortriptyline-induced 15-LOX expression, thus 
suggesting that alpha-1 adrenergic receptor activation is indeed essential for 
antidepressant-induced 15-LOX expression. Real-time RT-PCR results was 
supported by Western blot results where maprotiline treatment increased 15-
LOX protein expression and this increase was abolished by prazosin 
treatment. 
Overall, our preliminary results showed an increase in 15-LOX 
expression after antidepressant treatment and this increase involved alpha-1 
adrenergic receptor activation. Increasing 15-LOX expression coupled with 
higher DHA production due to antidepressant-induced iPLA2 expression will 
subsequently lead to enhanced levels of resolvins and neuroprotectins, 
potentially enhancing neural plasticity. Antidepressant treatment has been 
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shown to enhance neurogenesis and increase plasticity in the adult human 
brain (Warner-Schmidt and Duman, 2006; Pittenger and Duman, 2008; 
Castren and Hen, 2013). In addition, RvD1 was shown to attenuate NMDA 
receptor phosphorylation and normalize the spinal synaptic plasticity under 
pain conditions (Xu et al., 2010; Quan-Xin et al., 2012). Together, our results 
suggest that besides inducing iPLA2 and increasing the production of DHA, 
antidepressants with strong noradrenaline reuptake inhibition activity also has 
an effect on enzymes affecting DHA, most notably 15-LOX. The increase in 
both iPLA2 and 15-LOX may then lead to an overall increase in DHA and its 
metabolites which may activate the prefrontal cortex to stimulate the PAG and 
subsequent descending pain inhibitory pathway. Thus, it is possible that 
besides involving iPLA2, the effects of antidepressants on plasticity and 
antinociception could also potentially include activation of 15-LOX and 
subsequent production of resolvins and neuroprotectins although additional 
work is needed to investigate this further. 
  









Chapter 6: Conclusions 
  




In the first part of this study, we investigated the role of prefrontal 
cortical iPLA2 in antidepressant-induced antinociception. Mice that received 
maprotiline injection showed increased iPLA2 mRNA and protein expression 
in the prefrontal cortex, and reduced nociceptive responses in a carrageenan 
mouse model of inflammatory orofacial pain. Injection of antisense 
oligonucleotide to iPLA2 in the dorsolateral prefrontal cortex abolished the 
antinociceptive effect of maprotiline. In contrast, iPLA2 antisense injection in 
the somatosensory cortex had no effect on antinociception. Lipidomic analysis 
showed decreased PC and increased LPC lipid species in the prefrontal cortex 
after maprotiline treatment, indicating increased iPLA2 enzymatic activity and 
endogenous release of DHA and EPA. These changes were blocked by 
intracortical iPLA2 antisense injection. Together, results from the first part of 
this study indicate an important role of prefrontal cortical iPLA2 in the 
antinociceptive effect of maprotiline, and suggest the involvement of iPLA2 
not only in the antidepressive, but also antinociceptive effects of maprotiline 
and possibly other similar antidepressants.  
In the second part of this study, we elucidated the potential cellular 
mechanisms involved in the regulation of iPLA2 expression induction. 
Treatment of SH-SY5Y neuroblastoma cells with maprotiline and another 
TCA with strong noradrenaline reuptake inhibition activity, nortriptyline, as 
well as the alpha-1 adrenergic receptor agonist, phenylephrine, resulted in 
increased iPLA2 expression. This increase was blocked by inhibitors of the 
MAPK/ERK signaling cascade, SREBP pathway and the alpha-1 adrenergic 
receptor. In addition, maprotiline and phenylephrine increased the binding of 
Chapter 6: Conclusions 
148 
 
SREBP-2 to the SRE region on the iPLA2 gene, as determined by EMSA. 
Together, our results indicate that stimulation of alpha-1 adrenergic receptors 
causes increased iPLA2 expression via MAPK/ERK and SREBP pathways. 
We have shown that stimulation of alpha-1 adrenergic receptors by 
maprotiline and nortriptyline led to an increase in iPLA2 expression and 
activity. Thus, in the third part of this study, we studied the possibility that 
other enzymes affecting DHA such as 15-LOX may also be regulated in the 
same way by maprotiline and other similar antidepressants. Overall, our 
results showed an increase in 15-LOX expression after maprotiline and 
nortriptyline treatment and this increase was suggested to be associated with 
alpha-1 adrenergic receptor activation. Increasing 15-LOX expression coupled 
with more DHA production due to antidepressant-induced iPLA2 expression 
may subsequently lead to enhanced levels of resolvins and neuroprotectins. 
In conclusion, it was suggested that prefrontal cortical iPLA2 has an 
important role in the antinociceptive effect of antidepressants especially those 
with strong noradrenaline reuptake inhibition activity such as maprotiline. Our 
results also showed that the induction of iPLA2 expression is potentially 
regulated by alpha-1 adrenergic receptors, MAPK/ERK signaling pathway and 
SREBP-2. Additionally, we found that 15-LOX is similarly increased by 
maprotiline and nortriptyline treatment. It is possible that antidepressant 
treatment with strong noradrenaline reuptake inhibition activity like 
maprotiline will first stimulate alpha-1 adrenergic receptors by increasing 
noradrenaline levels in the synaptic cleft (Fig. 6.1A). The stimulated alpha-1 
adrenergic receptors will lead to activation of the MAPK/ERK signaling 
pathway, in particular ERK1/2, which then induce phosphorylation of SREBP-
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2 as well as increase SREBP-2 expression and stimulate its transcriptional 
activity (Fig 3.47B). Activated SREBP-2 will enter the nucleus and bind to the 
SRE sequence on the iPLA2 gene promoter, increasing iPLA2 expression (Fig 
3.47B). Increased iPLA2 expression will lead to higher release of DHA from 
glycerophospholipids and the generated DHA can be further metabolized by 
15-LOX which undergoes a concurrent increase in expression after 
antidepressant treatment (Fig. 6.1B). Increased DHA and its metabolites may 
then potentially facilitate activity or plasticity in the dorsolateral prefrontal 
cortex to stimulate the PAG and descending pain inhibitory pathway (Fig. 
6.1C). The potential mechanisms and signaling pathways involved in 
antidepressant-induced antinociception is summarized in Fig. 6.2. 
 
 





Fig. 6.1 Diagram showing the potential mechanisms and signaling pathways 
involved in antidepressant-induced antinociception in the (A) synaptic cleft, 
(B) neuronal cell and (C) brain. 
 
 




Fig. 6.2 Summary of the potential mechanisms and signaling pathways 
involved in antidepressant-induced antinociception. 
 
Nonetheless, it is vital to bear in mind that there are some limitations to 
our current study and additional work is necessary to further validate the 
potential mechanisms as well as pathways involved in the antidepressant-
induced antinociception suggested above. Future research directions include 
trying out other different antidepressants to investigate their effects on iPLA2 
and whether their antinociceptive activities are similarly affected by prefrontal 
cortical iPLA2 knockdown. It is possible that nortriptyline, which was shown 
to increase iPLA2 expression and has a similarly strong activity on 
noradrenaline reuptake inhibition as maprotiline, may likewise be affected by 
prefrontal cortical knockdown of iPLA2. Our results also showed that the 
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antinociceptive effect of amitriptyline was unaffected by prefrontal cortical 
iPLA2 inhibition, suggesting an alternative pathway and mechanism for 
antidepressant-induced antinociception which does not solely rely on 
prefrontal cortical iPLA2. It is possible that the antinociceptive effect of 
antidepressants with strong noradrenaline reuptake inhibition activity such as 
maprotiline involves iPLA2 while antidepressants with weaker noradrenaline 
reuptake inhibition activity and stronger serotonin reuptake inhibition activity 
such as amitriptyline induces antinociception without involving iPLA2. Thus, 
it is imperative to examine other different antidepressants to study their effect 
on iPLA2 and whether prefrontal cortical iPLA2 is essential for their 
antinociceptive activities. We would also need additional in vivo prefrontal 
cortical data in the future to further support our in vitro findings. 
Another possible future study is to supplement DHA to maprotiline-
treated mice and determine whether supplementation of DHA can salvage and 
prevent the abolishment of maprotiline-induced antinociception when 
prefrontal cortical iPLA2 is inhibited. More work can also be done on 15-LOX 
to investigate its role in pain and whether knockdown of 15-LOX will affect 
nociception. In addition, direct measurement of the levels of DHA and its 
metabolites in the prefrontal cortex can be performed to further substantiate 
our results in this study. 
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